<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.1d3" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">PLoS Negl Trop Dis</journal-id>
<journal-id journal-id-type="publisher-id">plos</journal-id>
<journal-id journal-id-type="pmc">plosntds</journal-id>
<journal-title-group>
<journal-title>PLOS Neglected Tropical Diseases</journal-title>
</journal-title-group>
<issn pub-type="epub">1935-2735</issn>
<publisher>
<publisher-name>Public Library of Science</publisher-name>
<publisher-loc>San Francisco, CA USA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1371/journal.pntd.0007098</article-id>
<article-id pub-id-type="publisher-id">PNTD-D-18-01902</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>The Role of Interleukin-1 cytokine family (IL-1β, IL-37) and interleukin-12 cytokine family (IL-12, IL-35) in eumycetoma infection pathogenesis</article-title>
<alt-title alt-title-type="running-head">Interleukins role in mycetoma</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" xlink:type="simple">
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0001-7004-7814</contrib-id>
<name name-style="western">
<surname>Abushouk</surname>
<given-names>Amir</given-names>
</name>
<role content-type="http://credit.casrai.org/">Conceptualization</role>
<role content-type="http://credit.casrai.org/">Data curation</role>
<role content-type="http://credit.casrai.org/">Formal analysis</role>
<role content-type="http://credit.casrai.org/">Writing – original draft</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Nasr</surname>
<given-names>Amre</given-names>
</name>
<role content-type="http://credit.casrai.org/">Conceptualization</role>
<role content-type="http://credit.casrai.org/">Data curation</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
<xref ref-type="aff" rid="aff003"><sup>3</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Masuadi</surname>
<given-names>Emad</given-names>
</name>
<role content-type="http://credit.casrai.org/">Conceptualization</role>
<role content-type="http://credit.casrai.org/">Data curation</role>
<role content-type="http://credit.casrai.org/">Formal analysis</role>
<role content-type="http://credit.casrai.org/">Writing – original draft</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff004"><sup>4</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Allam</surname>
<given-names>Gamal</given-names>
</name>
<role content-type="http://credit.casrai.org/">Conceptualization</role>
<role content-type="http://credit.casrai.org/">Data curation</role>
<role content-type="http://credit.casrai.org/">Formal analysis</role>
<role content-type="http://credit.casrai.org/">Writing – original draft</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff005"><sup>5</sup></xref>
<xref ref-type="aff" rid="aff006"><sup>6</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Siddig</surname>
<given-names>Emmanuel E.</given-names>
</name>
<role content-type="http://credit.casrai.org/">Conceptualization</role>
<role content-type="http://credit.casrai.org/">Data curation</role>
<role content-type="http://credit.casrai.org/">Formal analysis</role>
<role content-type="http://credit.casrai.org/">Methodology</role>
<role content-type="http://credit.casrai.org/">Writing – original draft</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff007"><sup>7</sup></xref>
</contrib>
<contrib contrib-type="author" corresp="yes" xlink:type="simple">
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-4922-7321</contrib-id>
<name name-style="western">
<surname>Fahal</surname>
<given-names>Ahmed H.</given-names>
</name>
<role content-type="http://credit.casrai.org/">Conceptualization</role>
<role content-type="http://credit.casrai.org/">Data curation</role>
<role content-type="http://credit.casrai.org/">Formal analysis</role>
<role content-type="http://credit.casrai.org/">Methodology</role>
<role content-type="http://credit.casrai.org/">Supervision</role>
<role content-type="http://credit.casrai.org/">Writing – original draft</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff007"><sup>7</sup></xref>
<xref ref-type="corresp" rid="cor001">*</xref>
</contrib>
</contrib-group>
<aff id="aff001"><label>1</label> <addr-line>Department of Basic Medical Sciences, College of Medicine, King Saud Bin Abdul-Aziz University for Health Sciences, Jeddah, Kingdom of Saudi Arabia</addr-line></aff>
<aff id="aff002"><label>2</label> <addr-line>King Abdullah International Medical Research Centre, National Guard Health Affairs, Riyadh, Kingdom of Saudi Arabia</addr-line></aff>
<aff id="aff003"><label>3</label> <addr-line>Department of Basic Medical Sciences, College of Medicine, King Saud Bin Abdul-Aziz University for Health Sciences, Riyadh, Kingdom of Saudi Arabia</addr-line></aff>
<aff id="aff004"><label>4</label> <addr-line>Research Unit, Department of Medical Education, College of Medicine-Riyadh, King Saud Bin Abdul-Aziz University for Health Sciences, Riyadh, Kingdom of Saudi Arabia</addr-line></aff>
<aff id="aff005"><label>5</label> <addr-line>Department of Microbiology and Immunology, College of Medicine, Taif University, Taif, Saudi Arabia</addr-line></aff>
<aff id="aff006"><label>6</label> <addr-line>Immunology Section, Department of Zoology, Faculty of Science, Beni-Suef University, Beni-Suef, Egypt</addr-line></aff>
<aff id="aff007"><label>7</label> <addr-line>Mycetoma Research Centre, University of Khartoum, Khartoum, Sudan</addr-line></aff>
<contrib-group>
<contrib contrib-type="editor" xlink:type="simple">
<name name-style="western">
<surname>Samy</surname>
<given-names>Abdallah M.</given-names>
</name>
<role>Editor</role>
<xref ref-type="aff" rid="edit1"/>
</contrib>
</contrib-group>
<aff id="edit1"><addr-line>Faculty of Science, Ain Shams University (ASU), EGYPT</addr-line></aff>
<author-notes>
<fn fn-type="conflict" id="coi001">
<p>The authors have declared that no competing interests exist.</p>
</fn>
<corresp id="cor001">* E-mail: <email xlink:type="simple">ahfahal@hotmail.com</email>, <email xlink:type="simple">ahfahal@uofk.edu</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>4</day>
<month>4</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="collection">
<month>4</month>
<year>2019</year>
</pub-date>
<volume>13</volume>
<issue>4</issue>
<elocation-id>e0007098</elocation-id>
<history>
<date date-type="received">
<day>14</day>
<month>12</month>
<year>2018</year>
</date>
<date date-type="accepted">
<day>18</day>
<month>3</month>
<year>2019</year>
</date>
</history>
<permissions>
<copyright-year>2019</copyright-year>
<copyright-holder>Abushouk et al</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="info:doi/10.1371/journal.pntd.0007098"/>
<abstract>
<p>Mycetoma is a neglected tropical disease, endemic in many tropical and subtropical regions, characterised by massive deformity and disability and can be fatal if untreated early and appropriately. Interleukins (IL) -35 and IL-37 are newly discovered cytokines that play an important role in suppressing the immune system. However, the expression of these interleukins in patients with <italic>Madurella mycetomatis (M</italic>. <italic>mycetomatis)</italic> induced eumycetoma has not yet been explored. The aim of this study is to determine the levels of IL-1 family (IL-1β, IL-37) and IL-12 family (IL-12, IL-35) in a group of these patients and the association between these cytokines levels and the patients’ demographic characteristics. The present, case-control study was conducted at the Mycetoma Research Centre, Soba University Hospital, University of Khartoum, Sudan and it included 140 individuals. They were divided into two groups; group I: healthy controls [n = 70; median age 25 years (range 12 to 70 years)]. Group II: mycetoma patients [n = 70 patients; median age 25 (range 13 to 70 years)]. Cytokines levels were measured in sera using enzyme linked immunosorbent assay (ELISA). There was a significant negative correlation between IL-1β and IL-12 levels and lesion size and disease duration, while IL-37 and IL-35 levels were significantly positively correlated with both lesion size and disease duration. The analysis of the risk factors of higher circulatory levels of IL-37 in patients of mycetoma showed a negative significant association with IL-1β cytokine, where a unit increment in IL-1β will decrease the levels of IL-37 by 35.28 pg/ml. The levels of IL-37 among the patients with a duration of mycetoma infection ≤ 1 year were significantly low by an average of 18.45 pg/ml compared to patients with a mycetoma infection’s duration of ≥ 5years (reference group). Furthermore, the risk factors of higher levels of IL-35 in mycetoma patients revealed a negative significant association with IL-12, as a unit increment in IL-12 decreases the levels of IL-35 by 8.99 pg/ml (<italic>p</italic> &lt; 0.001). Levels of IL-35 among the patients with duration of mycetoma infection ≤ one year were significantly low on average by 41.82 pg/ml (<italic>p</italic> value = 0.002) compared to patients with a duration of mycetoma infection ≥ 5 years (reference group). In conclusion, this study indicates that both IL-35 and IL-37 are negatively associated with the levels of IL-1β and IL-12 in eumycetoma mycetoma infection; and high levels of IL-37 and IL-35 may have a negative impact on disease progression.</p>
</abstract>
<abstract abstract-type="summary">
<title>Author summary</title>
<p>Mycetoma is a progressive chronic granulomatous fungal or bacterial infection that may result in massive destruction of subcutaneous tissues, muscles and bones. Mycetoma is a neglected disease which is endemic in many tropical and subtropical areas. If the disease is not treated properly, eventually it ends up with amputation and adverse medical, health and socioeconomic effects on patients and the community. Previous data suggested a crucial role of adaptive immunity in host resistance to causative agents and in the disease progress. The recently identified IL-35 and IL-37 cytokines revealed an important role in immune suppression. Nevertheless, the expression of these interleukins in patients with mycetoma has not yet been investigated. Therefore, the present case-control study aimed to determine the levels of IL-1 family (IL-1β, IL-37) and IL-12 family (IL-12, IL-35) in these patients and the association between these cytokines levels and the patients’ demographic characteristics. The results of this study showed that, the levels of IL-37 and IL-35 were consistently positively correlated with different diameters of mycetoma lesions as well as its duration. However, the levels of IL-1β and IL-12 were consistently negatively correlated with different diameters of lesions and the duration of mycetoma infection. The analysis of the risk factors of higher circulatory levels of IL-37 in patients of mycetoma showed a negative significant association with IL-1β cytokine Furthermore, the risk factors of higher levels of IL-35 in patients of mycetoma revealed a negative significant association with IL-12. These findings uncover a possible the role of IL-35 and IL-37 in the pathogenesis of mycetoma, and may declare their potential value in treatment of mycetoma.</p>
</abstract>
<funding-group>
<funding-statement>AN was financially supported by King Abdullah International Medical Research Centre (KAIMRC), National Guard Health Affairs, Kingdom of Saudi Arabia, grant (No. RC13/246). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement>
</funding-group>
<counts>
<fig-count count="0"/>
<table-count count="9"/>
<page-count count="18"/>
</counts>
<custom-meta-group>
<custom-meta>
<meta-name>PLOS Publication Stage</meta-name>
<meta-value>vor-update-to-uncorrected-proof</meta-value>
</custom-meta>
<custom-meta>
<meta-name>Publication Update</meta-name>
<meta-value>2019-04-25</meta-value>
</custom-meta>
<custom-meta id="data-availability">
<meta-name>Data Availability</meta-name>
<meta-value>All relevant data are within the manuscript and its Supporting Information files.</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="sec001" sec-type="intro">
<title>Introduction</title>
<p>Mycetoma is a chronic granulomatous subcutaneous inflammatory disease, caused by certain bacteria (actinomycetoma) or fungi (eumycetoma). This infection progresses to affect the deep structures and bones leading to massive destruction, deformities and disabilities [<xref ref-type="bibr" rid="pntd.0007098.ref001">1</xref>]. It constitutes a major health problem in many tropical and subtropical countries and it is highly endemic in Sudan, Mexico, and India. In Sudan, more than 8500 patients were managed at the Mycetoma Research Centre in Khartoum, of whom 70% were infected with the fungus <italic>M</italic>. <italic>mycetomatis</italic>. The disease affects all age groups, but it occurs most commonly in young men at the age group 20 to 40 years [<xref ref-type="bibr" rid="pntd.0007098.ref002">2</xref>]. The disease is usually painless and the clinical diagnosis is commonly based on the presence of subcutaneous mass, multiple sinuses and seropurulent discharge with grains. Treatment opportunities comprise of various chemotherapeutics agents and wide surgical excision of the infected tissues and may possibly end up with limb amputation [<xref ref-type="bibr" rid="pntd.0007098.ref003">3</xref>].</p>
<p>Although most individuals in endemic areas have antibodies against the causative agent of mycetoma; only few develop the disease [<xref ref-type="bibr" rid="pntd.0007098.ref004">4</xref>]. Both innate and adaptive immunity play a role in host resistance to causative agents and in the development of disease. Therefore, T-cell responses seem to be important in the progress of mycetoma [<xref ref-type="bibr" rid="pntd.0007098.ref005">5</xref>, <xref ref-type="bibr" rid="pntd.0007098.ref006">6</xref>]. A T-helper (Th) 2-like response was reported in primary lesions and in draining lymph nodes in patients with <italic>Streptomyces somaliensis</italic> infection and after stimulation of peripheral blood mononuclear cells by <italic>M</italic>. <italic>mycetomatis</italic> antigens [<xref ref-type="bibr" rid="pntd.0007098.ref005">5</xref>, <xref ref-type="bibr" rid="pntd.0007098.ref007">7</xref>], whilst Th1 response was reported in the acute phase of infection and in healthy endemic controls [<xref ref-type="bibr" rid="pntd.0007098.ref008">8</xref>, <xref ref-type="bibr" rid="pntd.0007098.ref009">9</xref>]. Macrophages stimulated with live conidia of <italic>Pseudallescheria boydii</italic> also induced a Th2 response, whereas hyphae induced a Th1 response [<xref ref-type="bibr" rid="pntd.0007098.ref010">10</xref>]. Experimental infection of nude athymic rats and mice with <italic>Nocardia (N</italic>.<italic>) asteroids</italic> let to fatal disease dissemination [<xref ref-type="bibr" rid="pntd.0007098.ref011">11</xref>, <xref ref-type="bibr" rid="pntd.0007098.ref012">12</xref>]. In addition, T lymphocytes from previously immunised animals directly killed <italic>N</italic>. <italic>asteroides</italic> [<xref ref-type="bibr" rid="pntd.0007098.ref012">12</xref>, <xref ref-type="bibr" rid="pntd.0007098.ref013">13</xref>]. Moreover, Trevino-Villarreal and associates [<xref ref-type="bibr" rid="pntd.0007098.ref014">14</xref>] reported that <italic>N</italic>. <italic>brasiliensis</italic> cell wall-associated lipids are implicated in the development of experimental actinomycetoma and act principally by inhibiting several microbicidal effects of macrophages, including the inhibition of TNF-α production, phagocytosis, production of nitric oxide (NO), and bacterial killing. In addition, they demonstrated that <italic>the N</italic>. <italic>brasiliensis</italic> wall-associated lipids suppressed the expression of major histocompatibility complex class II (MHC II), CD80, and CD40 by dendritic cells (DCs) and strongly induced the production of TGF-β by these cells. It has been suggested that pre-existing Th2 environment caused by schistosomiasis promotes the development of mycetoma as patients with mycetoma were significantly more positive for schistosoma antibodies than healthy endemic controls [<xref ref-type="bibr" rid="pntd.0007098.ref009">9</xref>]. These findings suggested that Th2 like response and anti-inflammatory/immunosuppressive cytokines could have a negative impact on mycetoma development and disease progression.</p>
<p>IL-1 is a polypeptide which has two forms; IL-1α and IL-1β. It is involved in the acute-phase response and is accountable for several alterations that are related to the onset of various medical disorders [<xref ref-type="bibr" rid="pntd.0007098.ref015">15</xref>, <xref ref-type="bibr" rid="pntd.0007098.ref016">16</xref>]. It is demonstrated recently that higher levels of IL-1β cytokine are strongly associated with surgically treated mycetoma patients, in comparison to those treated without surgery [<xref ref-type="bibr" rid="pntd.0007098.ref017">17</xref>]. It is known that IL-1β is a pro-inflammatory cytokine that is involved in cell death coordination [<xref ref-type="bibr" rid="pntd.0007098.ref018">18</xref>]. IL-1β cytokine is cleaved into the mature, active form primarily by inflammasome dependent caspase activity [<xref ref-type="bibr" rid="pntd.0007098.ref018">18</xref>]. It is possibly that mature IL-1β secretion by macrophages activates IL-1 receptor type 1 (IL-1R1) on macrophages, fibroblasts and epithelial cells, inducing production of the CXC chemokine CXCL1/KC, which binds to CXCR2 on neutrophils and mediates recruitment of neutrophils from peripheral blood to stimulate inflammation at the site of mycetoma invasion. Therefore, these higher levels of IL-1β cytokine advocate a crucial role in <italic>M</italic>. <italic>mycetomatis</italic> pathogenesis.</p>
<p>IL-37, which is a member of the IL-1 family, has emerged as a potent anti-inflammatory cytokine that suppresses both innate and adaptive immune responses [<xref ref-type="bibr" rid="pntd.0007098.ref019">19</xref>]. Its role in human diseases is not completely understood yet [<xref ref-type="bibr" rid="pntd.0007098.ref020">20</xref>]. However, the anti-inflammatory properties of IL-37 have been associated with inflammatory diseases, such as systemic lupus erythematosus (SLE) [<xref ref-type="bibr" rid="pntd.0007098.ref021">21</xref>], and inflammatory bowel disease [<xref ref-type="bibr" rid="pntd.0007098.ref022">22</xref>]. It has been reported that IL-37 is negatively associated with pro-inflammatory cytokines such as IL-1β, IL-6, IL-17, TNF-α and IFN-γ in peripheral blood mononuclear cells (PBMCs) of patients with degenerative intervertebral discs [<xref ref-type="bibr" rid="pntd.0007098.ref023">23</xref>] and Graves’ disease (GD) [<xref ref-type="bibr" rid="pntd.0007098.ref024">24</xref>]. IL-37 protein level in PBMCs and DCs is up-regulated when stimulated by Toll-like receptor (TLR) ligands or pro-inflammatory cytokines [<xref ref-type="bibr" rid="pntd.0007098.ref025">25</xref>]. In vitro, over expression of IL-37 in macrophages or epithelial cells greatly inhibits the production of major pro-inflammatory cytokines such as TNF-α, IL-1α, IL-1β, IL-6, IFN-γ and macrophage inflammatory protein 2 [<xref ref-type="bibr" rid="pntd.0007098.ref025">25</xref>, <xref ref-type="bibr" rid="pntd.0007098.ref026">26</xref>]. In vivo, IL-37 transgene protects mice from lipopolysaccharides-induced shock and chemical-induced colitis [<xref ref-type="bibr" rid="pntd.0007098.ref019">19</xref>, <xref ref-type="bibr" rid="pntd.0007098.ref027">27</xref>]. IL-37 interferes with the innate protective anti-Candida host response by reducing the production of pro-inflammatory cytokines and suppressing neutrophil recruitment in response to Candida infection, resulting in an increased susceptibility to disseminated candidiasis [<xref ref-type="bibr" rid="pntd.0007098.ref028">28</xref>]. Moreover, IL-37 markedly reduced inflammasome activation and disease severity in murine aspergillosis [<xref ref-type="bibr" rid="pntd.0007098.ref029">29</xref>]. In addition to its role in innate immunity; IL-37 plays a pivotal role in regulating adaptive immunity by inducing T regulatory (T<sub>reg</sub>) cells and impairing activation of effector T-cell responses [<xref ref-type="bibr" rid="pntd.0007098.ref030">30</xref>]. To our knowledge, there has been no study to report the relationship between IL-37 and mycetoma pathogenesis so far.</p>
<p>Interleukin-12 (IL-12) is frequently denoted as a B cell cytokine, although it is mainly formed by innate immune cells, comprising epithelial cells, DCs, and macrophages [<xref ref-type="bibr" rid="pntd.0007098.ref031">31</xref>]. IL-12 is a multimer that plays a fundamental role in immune regulation and is extensively involved in infections. It binds to the heterodimeric IL-12 receptor, which is principally present in T cells and on natural killer (NK) cells [<xref ref-type="bibr" rid="pntd.0007098.ref031">31</xref>]. IL-12 induces Th1 responses [<xref ref-type="bibr" rid="pntd.0007098.ref032">32</xref>], which consequently increase the cytotoxic cytokines, in addition to IFN-γ by T cells [<xref ref-type="bibr" rid="pntd.0007098.ref031">31</xref>, <xref ref-type="bibr" rid="pntd.0007098.ref032">32</xref>].</p>
<p>IL-35 is a recently identified heterodimeric cytokine which belongs to the IL-12 cytokine family, composed of the subunits of IL-27; β chain Epstein-Barr-virus (EBV)-induced gene 3 (Ebi3) and IL-12α chain p35 [<xref ref-type="bibr" rid="pntd.0007098.ref033">33</xref>, <xref ref-type="bibr" rid="pntd.0007098.ref034">34</xref>]. IL-35 is a potent immunosuppressive cytokine produced by B regulatory cells (B<sub>reg</sub>) [<xref ref-type="bibr" rid="pntd.0007098.ref035">35</xref>], DCs [<xref ref-type="bibr" rid="pntd.0007098.ref036">36</xref>], and to a lesser extent, by endothelial cells, smooth muscle cells, and monocytes [<xref ref-type="bibr" rid="pntd.0007098.ref037">37</xref>]. The biological effect of IL-35 is poorly understood, however IL-35 is recognised as a typical anti-inflammatory cytokine, and the predominant mechanism of suppression is associated with its ability to suppress T cell proliferation and effector functions [<xref ref-type="bibr" rid="pntd.0007098.ref033">33</xref>, <xref ref-type="bibr" rid="pntd.0007098.ref038">38</xref>]. Given the direct immunosuppressive effect of IL-35, many studies have been conducted to evaluate its role in the development of several diseases. IL-35 can suppress several types of chronic inflammatory diseases such as inflammatory bowel disease [<xref ref-type="bibr" rid="pntd.0007098.ref026">26</xref>], and decreased the severity of collagen induced arthritis in animals via enhancement of IL-10 production [<xref ref-type="bibr" rid="pntd.0007098.ref039">39</xref>] and suppression of Th17 cells [<xref ref-type="bibr" rid="pntd.0007098.ref040">40</xref>]. In an asthma model, intra-tracheal instillation of IL-35 decreased disease severity by diminishing the Th2 cell counts [<xref ref-type="bibr" rid="pntd.0007098.ref041">41</xref>] and by reducing the production of IL-17 [<xref ref-type="bibr" rid="pntd.0007098.ref042">42</xref>]. In bacterial infections, Shen and associates [<xref ref-type="bibr" rid="pntd.0007098.ref035">35</xref>] found that mice without IL-35 expression demonstrated an obviously improved resistance to infection with the intracellular bacterial pathogen <italic>Salmonella typhimurium</italic>. In addition, IL-35 has been increased in the serum of adults and children with sepsis, and administration of anti-IL-35 p35 antibodies diminished dissemination of the bacteria in septic animals [<xref ref-type="bibr" rid="pntd.0007098.ref043">43</xref>]. Similarly, tuberculous patients exhibited an increase in serum IL-35 and in mRNA expression of both subunits of IL-35 (p35 and EBI3) in white blood cells and peripheral blood mononuclear cells [<xref ref-type="bibr" rid="pntd.0007098.ref044">44</xref>]. However, the role of IL-35 in mycetoma pathogenesis has not been highlighted yet.</p>
<p>With this background this study was set to determine the IL-1 cytokine family (IL-1β, IL-37) and IL-12 cytokine family (IL-12, IL-35) circulating levels of in patients infected with <italic>M</italic>. <italic>mycetomatis</italic>, and to explore the association between the pro-inflammatory/anti-inflammatory cytokine levels and the patients’ demographic characteristics. This is correlation may help to understand the pathogenesis of mycetoma disease.</p>
</sec>
<sec id="sec002" sec-type="materials|methods">
<title>Materials and methods</title>
<sec id="sec003">
<title>Study population</title>
<p>This case-control study was conducted at the Mycetoma Research Centre, Soba University Hospital, University of Khartoum, Sudan. After a written informed consent, blood samples were taken from patients and a matched control population living in the mycetoma endemic areas of Sudan between 2015 and 2016. Samples collection was previously described in details by Nasr and associates [<xref ref-type="bibr" rid="pntd.0007098.ref017">17</xref>].</p>
<p>In this study 140 individuals were enrolled; 49 (35%) were females and 91 (65%) were males with an overall median age of 25 years (range 12–70 years). Seventy patients were infected with <italic>M</italic>. <italic>mycetomatis</italic>. The study population was divided into two groups; group I: healthy controls [n = 70; median age 25 years (range 12 to 70 years)]. Group II: mycetoma patients [n = 70 patients; median age 25 (range 13 to 70 years)]. Both groups had a similar gender distribution, 54 (80%) were males in each group.</p>
<p>The diagnosis of eumycetoma was established by various techniques and that included imaging, molecular and histopathological techniques, and grain culture [<xref ref-type="bibr" rid="pntd.0007098.ref001">1</xref>, <xref ref-type="bibr" rid="pntd.0007098.ref045">45</xref>]. Surgical biopsies are obtained by a wide local incision under anaesthesia and appropriate surgical conditions as part of the routine patients’ treatment protocol [<xref ref-type="bibr" rid="pntd.0007098.ref045">45</xref>].</p>
<p>After medical examination, healthy controls were selected from blood bank donors or healthy volunteers to match the patient’s birthplace geographically. All healthy controls were questioned for acute or chronic infectious diseases, autoimmune family history and genetic disorders. Then all study participants gave their informed written consent and the study was approved by the Ethics Committee of the Faculty of Medicine, University of Khartoum, Sudan.</p>
</sec>
<sec id="sec004">
<title>Sample collection</title>
<p>One hundred μl of blood were collected on Whatman qualitative filter paper, Grade 1, circles, diam. 42.5 mm (Sigma-Aldrich Chemical Co., St. Louis, MO, USA) for determination of cytokines. The use of filter paper dried whole blood spots (DBS) for specimen collection was preferred to facilitate collection, storage and transportation of specimens and it is in line with the World Health Organization recommendations and also used in several previous studies [<xref ref-type="bibr" rid="pntd.0007098.ref046">46</xref>–<xref ref-type="bibr" rid="pntd.0007098.ref048">48</xref>]. Sera were extracted from filter-paper samples as described previously in details [<xref ref-type="bibr" rid="pntd.0007098.ref017">17</xref>].</p>
</sec>
<sec id="sec005">
<title>IL-1β, IL-37, IL-12 and IL-35 estimation</title>
<p>IL-1β, IL-37, and IL-12 were measured in the sera using commercially available enzyme linked immunosorbent assay (ELISA) kits (Abcam, Cambridge, UK). Serum levels of IL-35 were estimated using a sandwich ELISA commercial kit (Colorful Gene Biological Technology, Wuhan, China). Cytokine assays were performed in duplicates according to the manufacturers’ protocols. The sensitivity of Human ELISA kits for IL-1β, IL-37, IL-12 and IL-35 cytokines was 0.5 pg/ml.</p>
</sec>
<sec id="sec006">
<title>Statistical analysis</title>
<p>The data were managed by SPSS version 24.0 statistical software for Windows (IBM SPSS statistics) and appropriate statistical tests were used. The results are expressed as mean ± standard deviation (SD) or median with interquartile range (IQR). Spearman correlation test was used to evaluate the associations between serum IL-37 and IL-35 levels and laboratory values as well as serum cytokine levels. For non-parametric data, comparisons between the groups were performed using the Kruskal–Wallis test. One-way ANOVA was used for parametric data. General linear models were used to assess the risk factors for circulating IL-37 and IL-35 among mycetoma patients with different disease duration and lesions size of mycetoma infection adjusted with other variables. A test with a <italic>p</italic> value &lt;0.05 was considered statistically significant.</p>
</sec>
<sec id="sec007">
<title>Ethical considerations</title>
<p>This study was approved by the Ethics Committee of Soba University Hospital, Khartoum, Sudan (SUH, EC-17-029). Written informed consent was taken from all the participants before enrolment in the study. The work described here was performed in accordance with the Declaration of Helsinki [<xref ref-type="bibr" rid="pntd.0007098.ref049">49</xref>].</p>
</sec>
</sec>
<sec id="sec008" sec-type="results">
<title>Results</title>
<p>This study included 70 confirmed mycetoma patients and 70 healthy controls; gender and age matched. Fifty-six patients (80%) were males and 14 (20%) were females. Their ages ranged between 12 and 77 years and the median age was 25.5 years. The common age group [22 (31.4%)] was 19–24 years, 17 (22.9%) in the age group (25–29) years, and nine (12.9%) were 40 years old or more (<xref ref-type="table" rid="pntd.0007098.t001">Table 1</xref>). In this study, a total of 40 subjects [23 patients (32.9%) and 17 (24.3%) healthy controls] were domestic workers, 40 individuals [17 (24.3%) patients and 23 (32.9%) healthy controls] were students and 24 individuals [12 (17.1%) patients and 12 (17.1%) healthy controls] were farmers. Due to the prolonged illness and disability, 12 (17.1%) patients had lost their jobs while only 5 (7.1%) healthy controls were unemployed. A total of 6 individuals [5 (7.1%) patients and 1(1.4%) healthy controls] of the patients were housewives. A total of 13 individuals [1(1.4%) patients and 12 (17.1%) healthy controls] were employers (<xref ref-type="table" rid="pntd.0007098.t001">Table 1</xref>).</p>
<table-wrap id="pntd.0007098.t001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pntd.0007098.t001</object-id>
<label>Table 1</label> <caption><title>Demographic characteristics of the study populations.</title></caption>
<alternatives>
<graphic id="pntd.0007098.t001g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pntd.0007098.t001" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="left"/>
<th align="left"/>
<th align="left">Controls<break/>n = 70 (%)</th>
<th align="left">Mycetoma Patients n = 70 (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center" rowspan="2"><bold>Gender</bold></td>
<td align="center">Female</td>
<td align="center">14 (20)</td>
<td align="center">14 (20%)</td>
</tr>
<tr>
<td align="center">Male</td>
<td align="center">56 (80)</td>
<td align="center">56 (80)</td>
</tr>
<tr>
<td align="center" rowspan="5"><bold>Age groups (years)</bold></td>
<td align="center">12–18</td>
<td align="center">9 (12.9)</td>
<td align="center">9 (12.9)</td>
</tr>
<tr>
<td align="center">19–24</td>
<td align="center">22 (31.4)</td>
<td align="center">22 (31.4)</td>
</tr>
<tr>
<td align="center">25–29</td>
<td align="center">16 (22.9)</td>
<td align="center">16 (22.9)</td>
</tr>
<tr>
<td align="center">30–39</td>
<td align="center">14 (20.0)</td>
<td align="center">14 (20.0)</td>
</tr>
<tr>
<td align="center">≥40</td>
<td align="center">9 (12.9)</td>
<td align="center">9 (12.9)</td>
</tr>
<tr>
<td align="center" rowspan="6"><bold>Occupation</bold></td>
<td align="center">Worker</td>
<td align="center">17 (24.3)</td>
<td align="center">23 (32.9)</td>
</tr>
<tr>
<td align="center">Student</td>
<td align="center">23 (32.9)</td>
<td align="center">17 (24.3)</td>
</tr>
<tr>
<td align="center">Farmer</td>
<td align="center">12 (17.1)</td>
<td align="center">12 (17.1)</td>
</tr>
<tr>
<td align="center">Jobless</td>
<td align="center">5 (7.1)</td>
<td align="center">12 (17.1)</td>
</tr>
<tr>
<td align="center">House-wife</td>
<td align="center">1 (1.4)</td>
<td align="center">5 (7.1)</td>
</tr>
<tr>
<td align="center">Employer</td>
<td align="center">12 (17.1)</td>
<td align="center">1 (1.4)</td>
</tr>
<tr>
<td align="center"><bold>Discharge</bold><xref ref-type="table-fn" rid="t001fn001">*</xref></td>
<td align="center">No</td>
<td align="center"/>
<td align="center">35 (50)</td>
</tr>
<tr>
<td align="center"/>
<td align="center">Yes</td>
<td align="center"/>
<td align="center">35 (50)</td>
</tr>
<tr>
<td align="center" rowspan="3"><bold>Lesion diameter</bold><xref ref-type="table-fn" rid="t001fn001">*</xref></td>
<td align="center">Less than 5 cm</td>
<td align="center"/>
<td align="center">13 (18.6)</td>
</tr>
<tr>
<td align="center">5–10 cm</td>
<td align="center"/>
<td align="center">22 (31.4)</td>
</tr>
<tr>
<td align="center">More than 10 cm</td>
<td align="center"/>
<td align="center">35 (50.0)</td>
</tr>
<tr>
<td align="center" rowspan="3"><bold>Duration</bold><xref ref-type="table-fn" rid="t001fn001">*</xref></td>
<td align="center">≤1 year</td>
<td align="center"/>
<td align="center">22 (31.4)</td>
</tr>
<tr>
<td align="center">2–4 years</td>
<td align="center"/>
<td align="center">26 (37.1)</td>
</tr>
<tr>
<td align="center">≥5 years</td>
<td align="center"/>
<td align="center">22 (31.4)</td>
</tr>
<tr>
<td align="center"><bold>Medication</bold><xref ref-type="table-fn" rid="t001fn001">*</xref></td>
<td align="center">Itraconazole<break/>200 mg/day</td>
<td align="center"/>
<td align="center">46 (65.7)</td>
</tr>
<tr>
<td align="center"/>
<td align="center">Ketoconazole<break/>400 mg/day</td>
<td align="center"/>
<td align="center">24 (34.3)</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t001fn001"><p>*These parameters only for mycetoma patients.</p></fn>
</table-wrap-foot>
</table-wrap>
<sec id="sec009">
<title>Correlations between cytokine levels (IL-1β, IL-37, IL-12 and IL-35) stratified by the lesion diameter among mycetoma patients and control group</title>
<p>The levels of cytokines (IL-1β, IL-37, IL-12 and IL-35) were constitutively correlated among mycetoma patients with different lesions diameters. The levels of IL-1β were constitutively positively correlated with IL-12 and lesions diameter (<xref ref-type="table" rid="pntd.0007098.t002">Table 2</xref>). On the other hand, the levels of cytokine IL-1β were constitutively negatively correlated with IL-37 and IL-35 (<xref ref-type="table" rid="pntd.0007098.t002">Table 2</xref>). Furthermore, the levels of cytokine IL-37 were constitutively positively correlated with IL-35 (<xref ref-type="table" rid="pntd.0007098.t002">Table 2</xref>). However, the levels of cytokine IL-37 and IL-35 were constitutively negatively correlated with IL-12 (<xref ref-type="table" rid="pntd.0007098.t002">Table 2</xref>).</p>
<table-wrap id="pntd.0007098.t002" position="float">
<object-id pub-id-type="doi">10.1371/journal.pntd.0007098.t002</object-id>
<label>Table 2</label> <caption><title>Correlations between the serum levels of (IL-1β, IL-37, IL-12 and IL-35) by the lesion diameter and the control group.</title></caption>
<alternatives>
<graphic id="pntd.0007098.t002g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pntd.0007098.t002" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="center">Lesion diameter</th>
<th align="center">Cytokine Levels pg/ml</th>
<th align="center">IL-1β pg/ml</th>
<th align="center">IL-37 pg/ml</th>
<th align="center">IL-12 pg/ml</th>
<th align="center">IL-35 pg/ml</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center" rowspan="4"><bold>Controls (no lesion)</bold></td>
<td align="center">IL-1β</td>
<td align="center">1</td>
<td align="center"/>
<td align="center"/>
<td align="center"/>
</tr>
<tr>
<td align="center">IL-37</td>
<td align="center">0.115</td>
<td align="center">1</td>
<td align="center"/>
<td align="center"/>
</tr>
<tr>
<td align="center">IL-12</td>
<td align="center">0.137</td>
<td align="center">-0.023</td>
<td align="center">1</td>
<td align="center"/>
</tr>
<tr>
<td align="center">IL-35</td>
<td align="center">-0.125</td>
<td align="center">0.037</td>
<td align="center">0.065</td>
<td align="center">1</td>
</tr>
<tr>
<td align="center" rowspan="4"><bold>≤5 cm</bold></td>
<td align="center">IL-1β</td>
<td align="center">1</td>
<td align="center"/>
<td align="center"/>
<td align="center"/>
</tr>
<tr>
<td align="center">IL-37</td>
<td align="center">-0.992<xref ref-type="table-fn" rid="t002fn001">**</xref></td>
<td align="center">1</td>
<td align="center"/>
<td align="center"/>
</tr>
<tr>
<td align="center">IL-12</td>
<td align="center">0.987<xref ref-type="table-fn" rid="t002fn001">**</xref></td>
<td align="center">-0.996<xref ref-type="table-fn" rid="t002fn001">**</xref></td>
<td align="center">1</td>
<td align="center"/>
</tr>
<tr>
<td align="center">IL-35</td>
<td align="center">-0.924<xref ref-type="table-fn" rid="t002fn001">**</xref></td>
<td align="center">0.945<xref ref-type="table-fn" rid="t002fn001">**</xref></td>
<td align="center">-0.949<xref ref-type="table-fn" rid="t002fn001">**</xref></td>
<td align="center">1</td>
</tr>
<tr>
<td align="center" rowspan="4"><bold>5–10 cm</bold></td>
<td align="center">IL-1β</td>
<td align="center">1</td>
<td align="center"/>
<td align="center"/>
<td align="center"/>
</tr>
<tr>
<td align="center">IL-37</td>
<td align="center">-0.991<xref ref-type="table-fn" rid="t002fn001">**</xref></td>
<td align="center">1</td>
<td align="center"/>
<td align="center"/>
</tr>
<tr>
<td align="center">IL-12</td>
<td align="center">0.991<xref ref-type="table-fn" rid="t002fn001">**</xref></td>
<td align="center">-0.995<xref ref-type="table-fn" rid="t002fn001">**</xref></td>
<td align="center">1</td>
<td align="center"/>
</tr>
<tr>
<td align="center">IL-35</td>
<td align="center">-0.983<xref ref-type="table-fn" rid="t002fn001">**</xref></td>
<td align="center">0.989<xref ref-type="table-fn" rid="t002fn001">**</xref></td>
<td align="center">-0.983<xref ref-type="table-fn" rid="t002fn001">**</xref></td>
<td align="center">1</td>
</tr>
<tr>
<td align="center" rowspan="4"><bold>≥10 cm</bold></td>
<td align="center">IL-1β</td>
<td align="center">1</td>
<td align="center"/>
<td align="center"/>
<td align="center"/>
</tr>
<tr>
<td align="center">IL-37</td>
<td align="center">-0.998<xref ref-type="table-fn" rid="t002fn001">**</xref></td>
<td align="center">1</td>
<td align="center"/>
<td align="center"/>
</tr>
<tr>
<td align="center">IL-12</td>
<td align="center">0.969<xref ref-type="table-fn" rid="t002fn001">**</xref></td>
<td align="center">-0.971<xref ref-type="table-fn" rid="t002fn001">**</xref></td>
<td align="center">1</td>
<td align="center"/>
</tr>
<tr>
<td align="center">IL-35</td>
<td align="center">-0.994<xref ref-type="table-fn" rid="t002fn001">**</xref></td>
<td align="center">0.995<xref ref-type="table-fn" rid="t002fn001">**</xref></td>
<td align="center">-0.964<xref ref-type="table-fn" rid="t002fn001">**</xref></td>
<td align="center">1</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t002fn001"><p>** Spearman’s rho Correlation is significant at the 0.01 level (2-tailed).</p></fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="sec010">
<title>Correlations between cytokine levels (IL-1β, IL-37, IL-12 and IL-35) stratified by the disease duration and control group</title>
<p>In the patients group, the levels of cytokines (IL-1β, IL-37, IL-12 and IL-35) were constitutively correlated with the duration of mycetoma infection. Levels of IL-1β showed a consistent positive correlation with IL-12 and negative correlation with IL-37 and IL-35 (<xref ref-type="table" rid="pntd.0007098.t003">Table 3</xref>). Whereas, levels of IL-37 were constitutively positively correlated with IL-35 (<xref ref-type="table" rid="pntd.0007098.t003">Table 3</xref>). However, the levels of IL-37 and IL-35 were constitutively negatively correlated with IL-12 (<xref ref-type="table" rid="pntd.0007098.t003">Table 3</xref>).</p>
<table-wrap id="pntd.0007098.t003" position="float">
<object-id pub-id-type="doi">10.1371/journal.pntd.0007098.t003</object-id>
<label>Table 3</label> <caption><title>Correlations between the serum levels of (IL-1β, IL-37, IL-12 and IL-35) by the duration of mycetoma infection and the control group.</title></caption>
<alternatives>
<graphic id="pntd.0007098.t003g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pntd.0007098.t003" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="center">Duration</th>
<th align="center">Cytokine Levels pg/ml</th>
<th align="center">IL-1β pg/ml</th>
<th align="center">IL-37 pg/ml</th>
<th align="center">IL-12 pg/ml</th>
<th align="center">IL-35 pg/ml</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center" rowspan="4"><bold>Control</bold></td>
<td align="center">IL-1β</td>
<td align="center">1</td>
<td align="center"/>
<td align="center"/>
<td align="center"/>
</tr>
<tr>
<td align="center">IL-37</td>
<td align="center">0.115</td>
<td align="center">1</td>
<td align="center"/>
<td align="center"/>
</tr>
<tr>
<td align="center">IL-12</td>
<td align="center">0.137</td>
<td align="center">-0.023</td>
<td align="center">1</td>
<td align="center"/>
</tr>
<tr>
<td align="center">IL-35</td>
<td align="center">-0.125</td>
<td align="center">0.037</td>
<td align="center">0.065</td>
<td align="center">1</td>
</tr>
<tr>
<td align="center" rowspan="4"><bold>≤1 Years</bold></td>
<td align="center">IL-1β</td>
<td align="center">1</td>
<td align="center"/>
<td align="center"/>
<td align="center"/>
</tr>
<tr>
<td align="center">IL-37</td>
<td align="center">-0.997<xref ref-type="table-fn" rid="t003fn001">**</xref></td>
<td align="center">1</td>
<td align="center"/>
<td align="center"/>
</tr>
<tr>
<td align="center">IL-12</td>
<td align="center">0.997<xref ref-type="table-fn" rid="t003fn001">**</xref></td>
<td align="center">-0.999<xref ref-type="table-fn" rid="t003fn001">**</xref></td>
<td align="center">1</td>
<td align="center"/>
</tr>
<tr>
<td align="center">IL-35</td>
<td align="center">-0.996<xref ref-type="table-fn" rid="t003fn001">**</xref></td>
<td align="center">0.997<xref ref-type="table-fn" rid="t003fn001">**</xref></td>
<td align="center">-0.995<xref ref-type="table-fn" rid="t003fn001">**</xref></td>
<td align="center">1</td>
</tr>
<tr>
<td align="center" rowspan="4"><bold>2–4 years</bold></td>
<td align="center">IL-1β</td>
<td align="center">1</td>
<td align="center"/>
<td align="center"/>
<td align="center"/>
</tr>
<tr>
<td align="center">IL-37</td>
<td align="center">-0.999<xref ref-type="table-fn" rid="t003fn001">**</xref></td>
<td align="center">1</td>
<td align="center"/>
<td align="center"/>
</tr>
<tr>
<td align="center">IL-12</td>
<td align="center">0.996<xref ref-type="table-fn" rid="t003fn001">**</xref></td>
<td align="center">-0.997<xref ref-type="table-fn" rid="t003fn001">**</xref></td>
<td align="center">1</td>
<td align="center"/>
</tr>
<tr>
<td align="center">IL-35</td>
<td align="center">-0.997<xref ref-type="table-fn" rid="t003fn001">**</xref></td>
<td align="center">0.997<xref ref-type="table-fn" rid="t003fn001">**</xref></td>
<td align="center">-0.994<xref ref-type="table-fn" rid="t003fn001">**</xref></td>
<td align="center">1</td>
</tr>
<tr>
<td align="center" rowspan="4"><bold>≥5 years</bold></td>
<td align="center">IL-1β</td>
<td align="center">1</td>
<td align="center"/>
<td align="center"/>
<td align="center"/>
</tr>
<tr>
<td align="center">IL-37</td>
<td align="center">-0.999<xref ref-type="table-fn" rid="t003fn001">**</xref></td>
<td align="center">1</td>
<td align="center"/>
<td align="center"/>
</tr>
<tr>
<td align="center">IL-12</td>
<td align="center">0.986<xref ref-type="table-fn" rid="t003fn001">**</xref></td>
<td align="center">-0.986<xref ref-type="table-fn" rid="t003fn001">**</xref></td>
<td align="center">1</td>
<td align="center"/>
</tr>
<tr>
<td align="center">IL-35</td>
<td align="center">-0.998<xref ref-type="table-fn" rid="t003fn001">**</xref></td>
<td align="center">0.997<xref ref-type="table-fn" rid="t003fn001">**</xref></td>
<td align="center">-0.986<xref ref-type="table-fn" rid="t003fn001">**</xref></td>
<td align="center">1</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t003fn001"><p>** Spearman’s rho Correlation is significant at the 0.01 level (2-tailed).</p></fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="sec011">
<title>Analysis of the serum levels of IL-1β, IL-37, IL-12 and IL-35 within the different lesion diameters among mycetoma patients and control groups</title>
<p>Circulating serum cytokine levels were determined in all mycetoma patients and were compared between the different lesion diameters among mycetoma patients and healthy controls. Overall, there was a significant difference in the levels of all studied cytokines between the four groups (Three levels of lesion diameter and the healthy controls), (<xref ref-type="table" rid="pntd.0007098.t004">Table 4</xref>). Distribution of IL-1β levels has decreased dramatically with lesion diameter [for lesion diameter ≤ 5 cm: the mean ± SD (3.39 ± 1.07); for 5–10 cm: (2.32 ± 0.05); for ≥ 10 cm: (2.08 ± 0.11), <italic>p</italic> value &lt; 0.001]. However, the circulating serum levels of IL-37 were significantly increased with lesion diameter [for lesion diameter ≤ 5 cm: the mean ± SD (107.92 ± 5.96); for 5–10 cm: (141.45 ± 12.96) and for ≥ 10 cm: (193.20 ± 15.01), <italic>p</italic> value &lt; 0.001], (<xref ref-type="table" rid="pntd.0007098.t004">Table 4</xref>).</p>
<table-wrap id="pntd.0007098.t004" position="float">
<object-id pub-id-type="doi">10.1371/journal.pntd.0007098.t004</object-id>
<label>Table 4</label> <caption><title>Analysis of the serum cytokine levels of (IL-1β, IL-37, IL-12 and IL-35) within the different lesion diameter among mycetoma patient and control groups.</title></caption>
<alternatives>
<graphic id="pntd.0007098.t004g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pntd.0007098.t004" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="center">Cytokines Levels pg/ml</th>
<th align="center">Lesion diameter</th>
<th align="center">Mean± SD</th>
<th align="center">Median</th>
<th align="center">(Q1-Q3)</th>
<th align="center">P-value<xref ref-type="table-fn" rid="t004fn001">*</xref></th>
</tr>
</thead>
<tbody>
<tr>
<td align="center" rowspan="4"><bold>IL-1β</bold></td>
<td align="center"><bold>Control</bold></td>
<td align="center">1.16± 3.15</td>
<td align="center">0.11</td>
<td align="center">0.3–0.6</td>
<td align="char" char="." rowspan="4"><bold>&lt;0.001</bold></td>
</tr>
<tr>
<td align="center"><bold>≤5 cm</bold></td>
<td align="center">3.39± 1.07</td>
<td align="center">2.45</td>
<td align="center">2.5–4.5</td>
</tr>
<tr>
<td align="center"><bold>5–10 cm</bold></td>
<td align="center">2.32± 0.05</td>
<td align="center">2.3</td>
<td align="center">2.3–2.3</td>
</tr>
<tr>
<td align="center"><bold>≥10 cm</bold></td>
<td align="center">2.08± 0.11</td>
<td align="center">1.97</td>
<td align="center">2.1–2.1</td>
</tr>
<tr>
<td align="center" rowspan="4"><bold>IL-37</bold></td>
<td align="center"><bold>Control</bold></td>
<td align="center">22.06± 2.39</td>
<td align="center">20</td>
<td align="center">22–24</td>
<td align="char" char="." rowspan="4"><bold>&lt;0.001</bold></td>
</tr>
<tr>
<td align="center"><bold>≤5 cm</bold></td>
<td align="center">107.92± 5.96</td>
<td align="center">104</td>
<td align="center">108–112</td>
</tr>
<tr>
<td align="center"><bold>5–10 cm</bold></td>
<td align="center">141.45± 12.96</td>
<td align="center">129</td>
<td align="center">143–152</td>
</tr>
<tr>
<td align="center"><bold>≥10 cm</bold></td>
<td align="center">193.20± 15.01</td>
<td align="center">184.17</td>
<td align="center">189–199</td>
</tr>
<tr>
<td align="center" rowspan="4"><bold>IL-12</bold></td>
<td align="center"><bold>Control</bold></td>
<td align="center">2.46± 1.02</td>
<td align="center">1.96</td>
<td align="center">2.4–2.5</td>
<td align="char" char="." rowspan="4"><bold>&lt;0.001</bold></td>
</tr>
<tr>
<td align="center"><bold>≤5 cm</bold></td>
<td align="center">25.22± 3.34</td>
<td align="center">23.2</td>
<td align="center">25–28</td>
</tr>
<tr>
<td align="center"><bold>5–10 cm</bold></td>
<td align="center">14.45± 3.32</td>
<td align="center">12.4</td>
<td align="center">12.9–18.2</td>
</tr>
<tr>
<td align="center"><bold>≥10 cm</bold></td>
<td align="center">9.65± 0.36</td>
<td align="center">9.49</td>
<td align="center">9.5–9.8</td>
</tr>
<tr>
<td align="center" rowspan="4"><bold>IL-35</bold></td>
<td align="center"><bold>Control</bold></td>
<td align="center">15.97± 2.6</td>
<td align="center">14.6</td>
<td align="center">16.4–18.2</td>
<td align="char" char="." rowspan="4"><bold>&lt;0.001</bold></td>
</tr>
<tr>
<td align="center"><bold>≤5 cm</bold></td>
<td align="center">255.15± 1.72</td>
<td align="center">253</td>
<td align="center">255–257</td>
</tr>
<tr>
<td align="center"><bold>5–10 cm</bold></td>
<td align="center">263.23± 3.26</td>
<td align="center">261</td>
<td align="center">262–267</td>
</tr>
<tr>
<td align="center"><bold>≥10 cm</bold></td>
<td align="center">449.71± 22.2</td>
<td align="center">430</td>
<td align="center">447–456</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t004fn001"><p>*P values are derived from non-parametric method; <italic>Kruskal Wallis</italic> test.</p></fn>
</table-wrap-foot>
</table-wrap>
<p>Our results showed a significant reduction of circulating IL-12 levels versus lesion diameter [for lesion diameter ≤ 5 cm: the mean ± SD (25.22±3.34); for 5–10 cm: (14.45± 3.32); for ≥ 10 cm: (9.65 ± 0.36), <italic>p</italic> value &lt; 0.001], (<xref ref-type="table" rid="pntd.0007098.t004">Table 4</xref>). Circulating levels of IL-35 were significantly increased with increasing lesions’ diameter [for lesion diameter ≤ 5 cm: the mean ± SD (255.15 ± 1.72); for 5–10 cm: (263.23 ± 3.26); ≥ 10 cm: (449.71 ± 22.2), <italic>p</italic> value &lt; 0.001], (<xref ref-type="table" rid="pntd.0007098.t004">Table 4</xref>).</p>
</sec>
<sec id="sec012">
<title>Analysis of the serum levels of IL-1β, IL-37, IL-12 and IL-35 among mycetoma patients stratified by different durations of mycetoma infection compared to the control group</title>
<p>Circulating levels of IL-1β had significantly decreased with increasing disease duration [(≤ 1 year; median = 2.3 pg/ml), (2–4 years; median = 2.2 pg/ml) and (≥ 5 years; median = 2.2 pg/ml)], <italic>p v</italic>alue = 0.017 (<xref ref-type="table" rid="pntd.0007098.t005">Table 5</xref>). Serum levels of IL-12 dramatically decreased with the increase in disease duration [(≤ 1 year; median = 12.5 pg/ml), (2–4 years; median = 10.2 pg/ml) and (≥ 5 years; median = 9.8 pg/ml)] and <italic>p</italic> value &lt; 0.001 (<xref ref-type="table" rid="pntd.0007098.t005">Table 5</xref>). However, circulating levels of IL-37 were positively increased with different durations of mycetoma infection [(≤ 1 year; median = 145 pg/ml), (2–4 years; median = 178 pg/ml) and (≥ 5 years; median = 185.2 pg/ml)], <italic>p</italic> value &lt;0.001 (<xref ref-type="table" rid="pntd.0007098.t005">Table 5</xref>). Similarly, serum levels of IL-35 were also significantly increased with increasing duration of mycetoma infection [(≤ 1 year; median = 262.5 pg/ml), (2–4 years; median = 423.5 pg/ml) and (≥ 5 years; median = 436 pg/ml)], <italic>p</italic> value &lt; 0.001 (<xref ref-type="table" rid="pntd.0007098.t005">Table 5</xref>).</p>
<table-wrap id="pntd.0007098.t005" position="float">
<object-id pub-id-type="doi">10.1371/journal.pntd.0007098.t005</object-id>
<label>Table 5</label> <caption><title>Analysis of the serum cytokine levels of (IL-1β, IL-37, IL-12 and IL-35) among mycetoma patient stratified by different duration of mycetoma infection compared to controls group.</title></caption>
<alternatives>
<graphic id="pntd.0007098.t005g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pntd.0007098.t005" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="center">Cytokines<break/>pg/ml</th>
<th align="left">Duration</th>
<th align="center">Mean± SD</th>
<th align="center">Median</th>
<th align="center">(Q1- Q3)</th>
<th align="left">P-value<xref ref-type="table-fn" rid="t005fn001">*</xref></th>
</tr>
</thead>
<tbody>
<tr>
<td align="center" rowspan="4"><bold>IL-1β</bold></td>
<td align="left">Control</td>
<td align="center">1.2± 3.1</td>
<td align="char" char=".">0.4</td>
<td align="center">(0.1–0.6)</td>
<td align="char" char="." rowspan="4">0.017</td>
</tr>
<tr>
<td align="left">≤1 year</td>
<td align="center">2.3± 0.1</td>
<td align="char" char=".">2.3</td>
<td align="center">(2.2–2.4)</td>
</tr>
<tr>
<td align="left">2–4 years</td>
<td align="center">2.6± 0.9</td>
<td align="char" char=".">2.2</td>
<td align="center">(2.1–2.4)</td>
</tr>
<tr>
<td align="left">≥5 years</td>
<td align="center">2.3± 0.5</td>
<td align="char" char=".">2.2</td>
<td align="center">(2.0–2.3)</td>
</tr>
<tr>
<td align="center" rowspan="4"><bold>IL-37</bold></td>
<td align="left">Control</td>
<td align="center">22.1± 2.4</td>
<td align="char" char=".">22.0</td>
<td align="center">(20–24)</td>
<td align="char" char="." rowspan="4">&lt;0.001</td>
</tr>
<tr>
<td align="left">≤1 year</td>
<td align="center">146.7± 28.4</td>
<td align="char" char=".">145.0</td>
<td align="center">(122–160)</td>
</tr>
<tr>
<td align="left">2–4 years</td>
<td align="center">160.9± 41.3</td>
<td align="char" char=".">178.0</td>
<td align="center">(127–190)</td>
</tr>
<tr>
<td align="left">≥5 years</td>
<td align="center">175.7± 33.9</td>
<td align="char" char=".">185.2</td>
<td align="center">(156–194)</td>
</tr>
<tr>
<td align="center" rowspan="4"><bold>IL-12</bold></td>
<td align="left">Control</td>
<td align="center">2.5± 1.0</td>
<td align="char" char=".">2.4</td>
<td align="center">(2.0–2.5)</td>
<td align="char" char="." rowspan="4">&lt;0.001</td>
</tr>
<tr>
<td align="left">≤1 year</td>
<td align="center">14.9± 5.0</td>
<td align="char" char=".">12.5</td>
<td align="center">(10.5–19.5)</td>
</tr>
<tr>
<td align="left">2–4 years</td>
<td align="center">15.0± 7.5</td>
<td align="char" char=".">10.2</td>
<td align="center">(9.5–19.4)</td>
</tr>
<tr>
<td align="left">≥5 years</td>
<td align="center">12.1± 5.4</td>
<td align="char" char=".">9.8</td>
<td align="center">(9.5–12.1)</td>
</tr>
<tr>
<td align="center" rowspan="4"><bold>IL-35</bold></td>
<td align="left">Control</td>
<td align="center">16.0± 2.6</td>
<td align="char" char=".">16.4</td>
<td align="center">(14.6–18.2)</td>
<td align="char" char="." rowspan="4">&lt;0.001</td>
</tr>
<tr>
<td align="left">≤1 year</td>
<td align="center">301.9± 75.9</td>
<td align="char" char=".">262.5</td>
<td align="center">(260–271)</td>
</tr>
<tr>
<td align="left">2–4 years</td>
<td align="center">363.8± 101.5</td>
<td align="char" char=".">423.5</td>
<td align="center">(260–447)</td>
</tr>
<tr>
<td align="left">≥5 years</td>
<td align="center">397.6± 88.1</td>
<td align="char" char=".">436.0</td>
<td align="center">(267–450)</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t005fn001"><p>*P values are derived from non-parametric method; Kruskal Wallis test.</p></fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="sec013">
<title>Risk factors for increased IL-37 levels in mycetoma patients with different lesion diameters</title>
<p>The analysis of the risk factors of higher levels of IL-37 in patients of mycetoma showed a significant negative association with IL-1β, where a unit increment in IL-1β decreases the levels of IL-37 by 9.1 pg/ml, <italic>p</italic> value = 0.008 (<xref ref-type="table" rid="pntd.0007098.t006">Table 6</xref>). Serum levels of IL-37 among the patients with lesion diameter ≤ 5 cm and 5–10 cm have significantly lower on average by 75.4% and 52.6%, respectively, compared to patients with lesion diameter ≥ 10 cm (reference group). Serum levels of IL-37 among the patients of mycetoma showed no significant difference between males and females, <italic>p</italic> value = 0.176 (<xref ref-type="table" rid="pntd.0007098.t006">Table 6</xref>). Circulating levels of IL-37 significantly decreased with increasing age groups [(19–24 years); <italic>p</italic> value = 0.010 and (30–39) years; <italic>p</italic> value = 0.029], (<xref ref-type="table" rid="pntd.0007098.t006">Table 6</xref>).</p>
<table-wrap id="pntd.0007098.t006" position="float">
<object-id pub-id-type="doi">10.1371/journal.pntd.0007098.t006</object-id>
<label>Table 6</label> <caption><title>Risk factors for circulating cytokines IL-37 pg/ml in mycetoma patients with different lesion diameters.</title></caption>
<alternatives>
<graphic id="pntd.0007098.t006g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pntd.0007098.t006" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="left" rowspan="2">variable</th>
<th align="center" rowspan="2">Category</th>
<th align="center" rowspan="2">B<xref ref-type="table-fn" rid="t006fn001"><sup>‡</sup></xref></th>
<th align="center">95% Confidence Interval</th>
<th align="center" rowspan="2">p-value</th>
</tr>
<tr>
<th align="center">(Lower to Upper)</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left"><bold>Intercept</bold></td>
<td align="center"/>
<td align="center">228.4</td>
<td align="center">(208.6 to 248.1)</td>
<td align="char" char=".">&lt;0.001</td>
</tr>
<tr>
<td align="left"><bold>IL-1β</bold></td>
<td align="center"/>
<td align="center">-9.1</td>
<td align="center">(-15.7 to -2.5)</td>
<td align="char" char=".">0.008</td>
</tr>
<tr>
<td align="left" rowspan="3"><bold>Lesion diameter</bold></td>
<td align="center"><bold>≤5 cm</bold></td>
<td align="center">-75.4</td>
<td align="center">(-88.4 to -62.3)</td>
<td align="char" char=".">&lt;0.001</td>
</tr>
<tr>
<td align="center"><bold>5–10 cm</bold></td>
<td align="center">-52.6</td>
<td align="center">(-64.3 to -40.8)</td>
<td align="char" char=".">&lt;0.002</td>
</tr>
<tr>
<td align="center"><bold>≥10 cm</bold></td>
<td align="center">0</td>
<td align="center"/>
<td align="center"/>
</tr>
<tr>
<td align="left" rowspan="2"><bold>Gender</bold></td>
<td align="center"><bold>Female</bold></td>
<td align="center">-5.3</td>
<td align="center">(-13.1 to 2.5)</td>
<td align="char" char=".">0.176</td>
</tr>
<tr>
<td align="center"><bold>Male</bold></td>
<td align="center">0</td>
<td align="center"/>
<td align="center"/>
</tr>
<tr>
<td align="left" rowspan="5"><bold>Age groups years</bold></td>
<td align="center"><bold>12–18</bold></td>
<td align="center">-11.7</td>
<td align="center">(-23.2 to -0.2)</td>
<td align="char" char=".">0.047</td>
</tr>
<tr>
<td align="center">19–24</td>
<td align="center">-13.3</td>
<td align="center">(-23.2 to -3.3)</td>
<td align="char" char="."><bold>0.010</bold></td>
</tr>
<tr>
<td align="center"><bold>25–29</bold></td>
<td align="center">-9.5</td>
<td align="center">(-20.0 to 1.1)</td>
<td align="char" char=".">0.079</td>
</tr>
<tr>
<td align="center"><bold>30–39</bold></td>
<td align="center">-11.8</td>
<td align="center">(-22.3 to -1.2)</td>
<td align="char" char="."><bold>0.029</bold></td>
</tr>
<tr>
<td align="center"><bold>≥40</bold></td>
<td align="center">0</td>
<td align="center"/>
<td align="center"/>
</tr>
<tr>
<td align="center" rowspan="2"><bold>Medication</bold></td>
<td align="center"><bold>Itraconazole</bold><break/><bold>200 mg/day</bold></td>
<td align="center">-5.7</td>
<td align="center">(-16.4 to 5)</td>
<td align="char" char=".">0.293</td>
</tr>
<tr>
<td align="center"><bold>Ketoconazole</bold><break/><bold>400 mg/day</bold></td>
<td align="center">0</td>
<td align="center"/>
<td align="center"/>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t006fn001"><p><sup>‡</sup>B (95%CI) adjusted with lesion diameter, gender, age groups and medical treatments.</p></fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="sec014">
<title>Risk factors for increasing circulating IL-35 and the patients’ demographic characteristics and lesion diameters</title>
<p>The analysis of the risk factors of higher serum levels of IL-35 in mycetoma patients showed no significant association with IL-12, <italic>p</italic> value = 0.182 (<xref ref-type="table" rid="pntd.0007098.t007">Table 7</xref>). Circulating levels of IL-35 among the patients with lesions’ diameter ≤ 5 cm and 5–10 cm were significantly decreased by 174.4% and 176.5, respectively; compared to patients with lesion diameter ≥ 10 cm (reference group), <italic>p</italic> value &lt; 0.001 (<xref ref-type="table" rid="pntd.0007098.t007">Table 7</xref>).</p>
<table-wrap id="pntd.0007098.t007" position="float">
<object-id pub-id-type="doi">10.1371/journal.pntd.0007098.t007</object-id>
<label>Table 7</label> <caption><title>Risk factors for circulating cytokines IL-35 pg/ml in mycetoma patients with different lesion diameters.</title></caption>
<alternatives>
<graphic id="pntd.0007098.t007g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pntd.0007098.t007" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="left"/>
<th align="left">Parameter</th>
<th align="center">B<xref ref-type="table-fn" rid="t007fn001"><sup>‡</sup></xref></th>
<th align="center">95% Confidence Interval<break/>(Lower to Upper)</th>
<th align="center">P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left"><bold>Intercept</bold></td>
<td align="left"/>
<td align="char" char=".">460.0</td>
<td align="center">(437.5 to 482.4)</td>
<td align="char" char="."><bold>&lt;0.001</bold></td>
</tr>
<tr>
<td align="left"><bold>IL-12</bold></td>
<td align="left"/>
<td align="char" char=".">-1.2</td>
<td align="center">(-2.9 to 0.6)</td>
<td align="char" char=".">0.182</td>
</tr>
<tr>
<td align="left" rowspan="3"><bold>Lesion diameter</bold></td>
<td align="left"><bold>≤5 cm</bold></td>
<td align="char" char=".">-174.4</td>
<td align="center">(-205.2 to -143.5)</td>
<td align="char" char="."><bold>&lt;0.001</bold></td>
</tr>
<tr>
<td align="left"><bold>5–10 cm</bold></td>
<td align="char" char=".">-176.5</td>
<td align="center">(-194.8 to -158.1)</td>
<td align="char" char="."><bold>&lt;0.001</bold></td>
</tr>
<tr>
<td align="left"><bold>≥10 cm</bold></td>
<td align="char" char=".">0.0</td>
<td align="center"/>
<td align="center"/>
</tr>
<tr>
<td align="left" rowspan="2"><bold>Gender</bold></td>
<td align="left"><bold>Female</bold></td>
<td align="char" char=".">-2.9</td>
<td align="center">(-13.4 to 7.5)</td>
<td align="char" char=".">0.575</td>
</tr>
<tr>
<td align="left"><bold>Male</bold></td>
<td align="char" char=".">0.0</td>
<td align="center"/>
<td align="center"/>
</tr>
<tr>
<td align="left" rowspan="5"><bold>Age groups years</bold></td>
<td align="left"><bold>12–18</bold></td>
<td align="char" char=".">5.6</td>
<td align="center">(-9.6 to 20.7)</td>
<td align="char" char=".">0.464</td>
</tr>
<tr>
<td align="left"><bold>19–24</bold></td>
<td align="char" char=".">-1.8</td>
<td align="center">(-14.7 to 11.2)</td>
<td align="char" char=".">0.786</td>
</tr>
<tr>
<td align="left"><bold>25–29</bold></td>
<td align="char" char=".">-2.5</td>
<td align="center">(-16.3 to 11.4)</td>
<td align="char" char=".">0.722</td>
</tr>
<tr>
<td align="left"><bold>30–39</bold></td>
<td align="char" char=".">-7.9</td>
<td align="center">(-21.8 to 6.0)</td>
<td align="char" char=".">0.258</td>
</tr>
<tr>
<td align="left"><bold>≥40</bold></td>
<td align="char" char=".">0.0</td>
<td align="center"/>
<td align="center"/>
</tr>
<tr>
<td align="left" rowspan="2"><bold>Medication</bold></td>
<td align="center"><bold>Itraconazole 200 mg/day</bold></td>
<td align="char" char=".">2.9</td>
<td align="center">(-11.4 to 17.3)</td>
<td align="char" char=".">0.683</td>
</tr>
<tr>
<td align="center"><bold>Ketoconazole 400 mg/day</bold></td>
<td align="char" char=".">0.0</td>
<td align="center"/>
<td align="center"/>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t007fn001"><p><sup>‡</sup>B (95%CI) adjusted with lesion diameter, gender, age groups and medical treatments.</p></fn>
</table-wrap-foot>
</table-wrap>
<p>Serum levels of IL-35 among mycetoma patients showed no significant difference between males and female, <italic>p</italic> value = 0.575 (<xref ref-type="table" rid="pntd.0007098.t007">Table 7</xref>). Circulating levels of IL-35 showed no significant association with the different age groups and different types of antifungal medication given (<xref ref-type="table" rid="pntd.0007098.t007">Table 7</xref>).</p>
</sec>
<sec id="sec015">
<title>Risk factors for circulating IL-37 and the patients’ demographic characteristics and disease durations</title>
<p>The analysis of the risk factors of higher circulatory levels of IL-37 in patients of mycetoma showed a negative significant association with IL-1β, where a unit increment in IL-1β decreases the levels of IL-37 by 35.28 pg/ml, <italic>p</italic> &lt; 0.001 (<xref ref-type="table" rid="pntd.0007098.t008">Table 8</xref>). Levels of IL-37 among patients with a disease duration ≤ 1 year had significantly decreased on average by 18.45 pg/ml compared to patients with a disease duration ≥ 5years (reference group). However, there was no significant difference in levels of IL-37 between patients with infection duration 2–4 years and ≥ 5 years, <italic>p</italic> value = 0.793 (<xref ref-type="table" rid="pntd.0007098.t008">Table 8</xref>). In addition, serum levels of IL-37 among the mycetoma patients showed no significant difference between males and females, <italic>p</italic> value = 0.627 (<xref ref-type="table" rid="pntd.0007098.t008">Table 8</xref>). Furthermore, the circulating levels of IL-37 had significantly decreased with increasing age groups [(19–24 years; <italic>p</italic> value = 0.022), 25–29 years; <italic>p</italic> value = 0.030 and (30–39) years; <italic>p</italic> value = 0.022], (<xref ref-type="table" rid="pntd.0007098.t008">Table 8</xref>). Interestingly, levels of IL-37 among mycetoma patients showed a statistically significant difference between itraconazole compared to ketoconazole, <italic>p</italic> &lt; 0.001 (<xref ref-type="table" rid="pntd.0007098.t008">Table 8</xref>).</p>
<table-wrap id="pntd.0007098.t008" position="float">
<object-id pub-id-type="doi">10.1371/journal.pntd.0007098.t008</object-id>
<label>Table 8</label> <caption><title>Risk factors for circulating cytokines IL-37 pg/ml among mycetoma patients with different duration of mycetoma infection.</title></caption>
<alternatives>
<graphic id="pntd.0007098.t008g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pntd.0007098.t008" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="left" rowspan="2"/>
<th align="center" rowspan="2">Parameter</th>
<th align="center" rowspan="2">B<sup>‡</sup></th>
<th align="center">95% Confidence Interval</th>
<th align="center" rowspan="2">P-value</th>
</tr>
<tr>
<th align="center">(Lower to Upper)</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center"><bold>Intercept</bold></td>
<td align="center"/>
<td align="center">436.50</td>
<td align="center">394.36 to 478.64</td>
<td align="char" char="."><bold>&lt;0.001</bold></td>
</tr>
<tr>
<td align="center"><bold>IL-12</bold></td>
<td align="center"/>
<td align="center">-8.99</td>
<td align="center">-10.73 to -7.25</td>
<td align="char" char="."><bold>&lt;0.001</bold></td>
</tr>
<tr>
<td align="center" rowspan="3"><bold>Duration of mycetoma infection</bold></td>
<td align="center"><bold>≤1 year</bold></td>
<td align="center">-41.82</td>
<td align="center">-67.31 to -16.32</td>
<td align="char" char="."><bold>0.002</bold></td>
</tr>
<tr>
<td align="center"><bold>2–4 years</bold></td>
<td align="center">-10.64</td>
<td align="center">-35.28 to 14.01</td>
<td align="char" char=".">0.391</td>
</tr>
<tr>
<td align="center"><bold>≥5 years</bold></td>
<td align="center">0</td>
<td align="center"/>
<td align="center"/>
</tr>
<tr>
<td align="center" rowspan="2"><bold>Gender</bold></td>
<td align="center"><bold>Female</bold></td>
<td align="center">-8.47</td>
<td align="center">-32.85 to 15.90</td>
<td align="char" char=".">0.49</td>
</tr>
<tr>
<td align="center"><bold>Male</bold></td>
<td align="center">0</td>
<td align="center"/>
<td align="center"/>
</tr>
<tr>
<td align="center" rowspan="5"><bold>Age groups years</bold></td>
<td align="center"><bold>12–18</bold></td>
<td align="center">9.23</td>
<td align="center">-29.02 to 47.48</td>
<td align="char" char=".">0.631</td>
</tr>
<tr>
<td align="center"><bold>19–24</bold></td>
<td align="center">8.00</td>
<td align="center">-24.05 to 40.06</td>
<td align="char" char=".">0.619</td>
</tr>
<tr>
<td align="center"><bold>25–29</bold></td>
<td align="center">-2.19</td>
<td align="center">-36.43 to 32.05</td>
<td align="char" char=".">0.899</td>
</tr>
<tr>
<td align="center"><bold>30–39</bold></td>
<td align="center">-30.58</td>
<td align="center">-66.01 to 4.84</td>
<td align="char" char=".">0.089</td>
</tr>
<tr>
<td align="center"><bold>≥40</bold></td>
<td align="center">0</td>
<td align="center"/>
<td align="center"/>
</tr>
<tr>
<td align="center" rowspan="2"><bold>Medication</bold></td>
<td align="center"><bold>Itraconazole</bold><break/><bold>200 mg/day</bold></td>
<td align="center">101.17</td>
<td align="center">78.40 to 123.95</td>
<td align="char" char="."><bold>&lt;0.001</bold></td>
</tr>
<tr>
<td align="center"><bold>Ketoconazole</bold><break/><bold>400 mg/day</bold></td>
<td align="center">0</td>
<td align="center"/>
<td align="center"/>
</tr>
</tbody>
</table>
</alternatives>
</table-wrap>
</sec>
<sec id="sec016">
<title>Risk factors for circulating IL-35 among mycetoma patients with different disease</title>
<p>The analysis of the risk factors of higher levels of IL-35 in patients of mycetoma revealed a negative significant association with IL-12; as a unit increment in IL-12 decreases the levels of IL-35 by 8.99 pg/ml, <italic>p</italic> value &lt; 0.001 (<xref ref-type="table" rid="pntd.0007098.t009">Table 9</xref>). Levels of IL-35 among the patients with a mycetoma with a disease duration of ≤ 1 year had significantly decreased, <italic>p</italic> value = 0.002, on average by 41.82 pg/ml compared to patients with a disease duration ≥ 5years (reference group), (<xref ref-type="table" rid="pntd.0007098.t009">Table 9</xref>). However, patients with an infection duration of 2–4 years and ≥ 5 years showed no significant difference in IL-35 levels, <italic>p</italic> value = 0.391. Furthermore, there was no significant difference (<italic>p</italic> value = 0.49) in IL-35 levels between male and female mycetoma sufferers (<xref ref-type="table" rid="pntd.0007098.t009">Table 9</xref>). Additionally, the circulating levels of IL-35 showed no significant association with the different age groups (<xref ref-type="table" rid="pntd.0007098.t009">Table 9</xref>). Interestingly, mycetoma patients who were treated with itraconazole showed significant increased levels of IL-35 compared to the patients treated with ketoconazole, <italic>p</italic> value &lt;0.001 (<xref ref-type="table" rid="pntd.0007098.t009">Table 9</xref>).</p>
<table-wrap id="pntd.0007098.t009" position="float">
<object-id pub-id-type="doi">10.1371/journal.pntd.0007098.t009</object-id>
<label>Table 9</label> <caption><title>Risk factors for circulating cytokines IL-35 pg/ml among mycetoma patients with different duration of mycetoma infection.</title></caption>
<alternatives>
<graphic id="pntd.0007098.t009g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pntd.0007098.t009" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="left" rowspan="2"/>
<th align="center" rowspan="2">Parameter</th>
<th align="center" rowspan="2">B<xref ref-type="table-fn" rid="t009fn001"><sup>‡</sup></xref></th>
<th align="center">95% Confidence Interval</th>
<th align="center" rowspan="2">P-value</th>
</tr>
<tr>
<th align="center">(Lower to Upper)</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center"><bold>Intercept</bold></td>
<td align="center"/>
<td align="center">436.50</td>
<td align="center">394.36 to 478.64</td>
<td align="char" char="."><bold>&lt;0.001</bold></td>
</tr>
<tr>
<td align="center"><bold>IL-12</bold></td>
<td align="center"/>
<td align="center">-8.99</td>
<td align="center">-10.73 to -7.25</td>
<td align="char" char="."><bold>&lt;0.001</bold></td>
</tr>
<tr>
<td align="center" rowspan="3"><bold>Duration of mycetoma infection</bold></td>
<td align="center"><bold>≤1 year</bold></td>
<td align="center">-41.82</td>
<td align="center">-67.31 to -16.32</td>
<td align="char" char="."><bold>0.002</bold></td>
</tr>
<tr>
<td align="center"><bold>2–4 years</bold></td>
<td align="center">-10.64</td>
<td align="center">-35.28 to 14.01</td>
<td align="char" char=".">0.391</td>
</tr>
<tr>
<td align="center"><bold>≥5 years</bold></td>
<td align="center">0</td>
<td align="center"/>
<td align="center"/>
</tr>
<tr>
<td align="center" rowspan="2"><bold>Gender</bold></td>
<td align="center"><bold>Female</bold></td>
<td align="center">-8.47</td>
<td align="center">-32.85 to 15.90</td>
<td align="char" char=".">0.49</td>
</tr>
<tr>
<td align="center"><bold>Male</bold></td>
<td align="center">0</td>
<td align="center"/>
<td align="center"/>
</tr>
<tr>
<td align="center" rowspan="5"><bold>Age groups years</bold></td>
<td align="center"><bold>12–18</bold></td>
<td align="center">9.23</td>
<td align="center">-29.02 to 47.48</td>
<td align="char" char=".">0.631</td>
</tr>
<tr>
<td align="center"><bold>19–24</bold></td>
<td align="center">8.00</td>
<td align="center">-24.05 to 40.06</td>
<td align="char" char=".">0.619</td>
</tr>
<tr>
<td align="center"><bold>25–29</bold></td>
<td align="center">-2.19</td>
<td align="center">-36.43 to 32.05</td>
<td align="char" char=".">0.899</td>
</tr>
<tr>
<td align="center"><bold>30–39</bold></td>
<td align="center">-30.58</td>
<td align="center">-66.01 to 4.84</td>
<td align="char" char=".">0.089</td>
</tr>
<tr>
<td align="center"><bold>≥40</bold></td>
<td align="center">0</td>
<td align="center"/>
<td align="center"/>
</tr>
<tr>
<td align="center" rowspan="2"><bold>Medication</bold></td>
<td align="center"><bold>Itraconazole</bold><break/><bold>200 mg/day</bold></td>
<td align="center">101.17</td>
<td align="center">78.40 to 123.95</td>
<td align="char" char="."><bold>&lt;0.001</bold></td>
</tr>
<tr>
<td align="center"><bold>Ketoconazole</bold><break/><bold>400 mg/day</bold></td>
<td align="center">0</td>
<td align="center"/>
<td align="center"/>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t009fn001"><p><sup>‡</sup>B (95%CI) adjusted with Duration of mycetoma infection, gender, age groups and medical treatments.</p></fn>
</table-wrap-foot>
</table-wrap>
</sec>
</sec>
<sec id="sec017" sec-type="conclusions">
<title>Discussion</title>
<p>Although mycetoma represents a major health problem in many tropical and subtropical areas, there is no prevention or control measures for this neglected disease [<xref ref-type="bibr" rid="pntd.0007098.ref022">22</xref>, <xref ref-type="bibr" rid="pntd.0007098.ref023">23</xref>]. In mycetoma endemic areas, most individuals have antibodies against the causative agents, however only few develop disease [<xref ref-type="bibr" rid="pntd.0007098.ref004">4</xref>]. Few researchers believed that patients who develop mycetoma seem to be deficient in their cell-mediated immunity [<xref ref-type="bibr" rid="pntd.0007098.ref006">6</xref>]. Hence, we aimed to investigate the profiles of the pro-inflammatory (IL-1β and IL-12) and the anti-inflammatory immunosuppressive (IL-37 and IL-35) cytokines among mycetoma patients and their association with disease characteristics. As far as we know, this is the first study addressing the relation between immunosuppressive cytokines (IL-37 and IL-35) and mycetoma infection. Our data showed that eumycetoma patients presented higher circulating levels of IL-1β, IL-12, IL-37 and IL-35 compared to controls. In addition, serum levels of IL-1β and IL-12 were significantly decreased with increasing lesions’ diameter and disease duration, whereas levels of IL-37 and IL-35 were significantly higher with increasing lesions’ diameter and disease duration. These findings indicate that immunosuppressive cytokines like IL-37 and IL-35, which could suppress cell-mediated immune responses, may exacerbate the disease progression.</p>
<p>Data of the current study clearly showed the serum levels of IL-1β and IL-12 in eumycetoma patients with different lesion size and disease duration were positively correlated with each other, and negatively correlated with IL-35 and IL-37. It has been demonstrated that the first line of innate immune response against mycetoma infection is by phagocytes, from which macrophages represent the major phagocytic cells [<xref ref-type="bibr" rid="pntd.0007098.ref050">50</xref>]. In general, protective immunity to fungal infections [<xref ref-type="bibr" rid="pntd.0007098.ref051">51</xref>] involves activation of TLRs generating inflammatory cytokines through pattern-recognition receptors and pathogen associated molecular patterns [<xref ref-type="bibr" rid="pntd.0007098.ref052">52</xref>, <xref ref-type="bibr" rid="pntd.0007098.ref053">53</xref>]. IL-1β and other pro-inflammatory cytokines are produced early in response to fungal infections and promote phagocytosis and other means of innate immune response [<xref ref-type="bibr" rid="pntd.0007098.ref054">54</xref>, <xref ref-type="bibr" rid="pntd.0007098.ref055">55</xref>]. Following inflammatory stimuli, several cell types including immune and non-immune cells produce IL-37, as a protective mechanism to prevent runaway inflammation and excessive tissue damage [<xref ref-type="bibr" rid="pntd.0007098.ref056">56</xref>]. IL-37 directly inhibits generation of pro-inflammatory cytokines and down-regulates macrophage cytokine release, and therefore innate immunity [<xref ref-type="bibr" rid="pntd.0007098.ref057">57</xref>, <xref ref-type="bibr" rid="pntd.0007098.ref058">58</xref>]. Moreover, IL-37 induces macrophages towards an M2-like phenotype [<xref ref-type="bibr" rid="pntd.0007098.ref059">59</xref>]. M1 macrophages are the most critical effector cells in the innate immune defense system and are characterised by high expression levels of iNOS, subsequent NO production and secretion of pro-inflammatory cytokines, such as IL-1β and IL-12 [<xref ref-type="bibr" rid="pntd.0007098.ref060">60</xref>]. However, M2 macrophages secrete anti-inflammatory cytokines, such as IL-10 [<xref ref-type="bibr" rid="pntd.0007098.ref061">61</xref>] and express arginase 1, which inhibits NO production, thus rendering these cells ineffective in killing infectious agents including fungal agents [<xref ref-type="bibr" rid="pntd.0007098.ref061">61</xref>, <xref ref-type="bibr" rid="pntd.0007098.ref062">62</xref>]. Furthermore, DCs expressing IL-37 secreted higher levels of IL-10 and reduced levels of IL-1β and IL-12. Therefore, the presence of IL-37 in DCs impairs their function in prime T cells and promotes their ability to induce Treg cells that produce IL-10, which is also a potent anti-inflammatory cytokine [<xref ref-type="bibr" rid="pntd.0007098.ref030">30</xref>]. Our results have consistently shown higher circulatory levels of IL-37 in patients of mycetoma which is negatively associated with IL-1β, as a unit increment in IL-1β decreases the levels of IL-37 by 35.28 pg/ml. Based on the aforementioned data, we can speculate that IL-37 could play a role in damping inflammatory response in mycetoma infection which leads to disease progression and this is not in the patient’s favor.</p>
<p>In the current work, the circulating levels of IL-1β and IL-12 in eumycetoma patients with different lesion size and disease duration were negatively correlated with IL-35; whereas serum levels of IL-35 were increased with increasing lesion size and disease duration, and levels of IL-1β and IL-12 simultaneously decreased. This may probably be an attempt to dampen ongoing inflammation. Both IL-1β and IL-12 have a pivotal role in inflammatory and cell-mediated immune responses. Macrophages, Th1 and cytotoxic T-cells (CTLs), which constitute the main component of cell-mediated immunity, play an important role in the protective immunity against mycetoma infection [<xref ref-type="bibr" rid="pntd.0007098.ref002">2</xref>]. As fatal dissemination of <italic>N</italic>. <italic>asteroids</italic> infection occurs in nude athymic rats and mice [<xref ref-type="bibr" rid="pntd.0007098.ref011">11</xref>, <xref ref-type="bibr" rid="pntd.0007098.ref012">12</xref>], T cells from previously immunized animals are able to kill <italic>N</italic>. <italic>asteroids</italic> in new infections [<xref ref-type="bibr" rid="pntd.0007098.ref012">12</xref>, <xref ref-type="bibr" rid="pntd.0007098.ref013">13</xref>]. IL-35 could suppress Th1 and macrophage responses [<xref ref-type="bibr" rid="pntd.0007098.ref063">63</xref>], whereas deficiency in IL-35 increases macrophage’s activation and induces Th1 responses [<xref ref-type="bibr" rid="pntd.0007098.ref035">35</xref>, <xref ref-type="bibr" rid="pntd.0007098.ref063">63</xref>]. The increased immunity found in mice lacking IL-35 is associated with a higher activation of macrophages and inflammatory T cells, as well as enhancing function of antigen-presenting cells [<xref ref-type="bibr" rid="pntd.0007098.ref035">35</xref>]. In another infection model, Cao and his co-workers reported higher serum levels of IL-35 in septic patients compared to controls, and IL-35 gradually increased with increased sepsis severity. Moreover, administration of anti-IL-35 antibodies diminished dissemination of the bacteria in septic animals and enhanced local neutrophil recruitment with increasing in inflammatory cytokines and chemokines production [<xref ref-type="bibr" rid="pntd.0007098.ref043">43</xref>]. Furthermore, IL-35 suppressed the proliferation of antigen-specific CTLs and IFN-γ production [<xref ref-type="bibr" rid="pntd.0007098.ref064">64</xref>]. Our data revealed that higher levels of IL-35 in patients with mycetoma is negatively associated with IL-12, where a unit increment in IL-12 decreases the levels of IL-35 by 8.99 pg/ml. This finding indicates that IL-35 may be a risk factor for mycetoma infection and have a negative role in the clinical presentation of the disease.</p>
<p>Prevalence of mycetoma infection may vary with age. Data from this study showed variation of mycetoma prevalence with age; 74.3% of the patients’ age were 19–39 years. This finding is consistent with previous studies which reported that mycetoma mostly affects ages between 20 and 40 years-old, In addition, our data demonstrated that mycetoma infection was predominant in males, as the male to female ratio in patient’s group was 4:1. This finding is running parallel with the results of a previous study which demonstrated that in a tertiary facility in Khartoum, Sudan, the male to female ratio is 4:1, whereas at the primary care level in White Nile State, Sudan, the reported male to female ratio was 1.6:1. Another studies reported that male to female ratios in mycetoma infections were in the range of 1.6–6.6:1 [<xref ref-type="bibr" rid="pntd.0007098.ref002">2</xref>]. The predominance of mycetoma in males may be attributed to increased exposure in men who engage in different manual labors including agricultural work. Moreover, influence of sex hormones might have a role in susceptibility to mycetoma infections and disease progression [<xref ref-type="bibr" rid="pntd.0007098.ref004">4</xref>, <xref ref-type="bibr" rid="pntd.0007098.ref065">65</xref>].</p>
<p>Our data showed that about, 50% of the patients have lesion diameter more than 10 cm. This result reflected that most mycetoma patients tend to present late with massive lesions. This finding could be attributed to the nature of mycetoma which is usually painless and slowly progressive. In addition, the lack of health facilities in endemic areas, the low socio-economic status of the affected patients and their poor health education [<xref ref-type="bibr" rid="pntd.0007098.ref001">1</xref>, <xref ref-type="bibr" rid="pntd.0007098.ref004">4</xref>, <xref ref-type="bibr" rid="pntd.0007098.ref066">66</xref>] are amongst the reasons why the current treatment of mycetoma is suboptimal, characterised by low cure rates and frequent recurrence often leading to amputation [<xref ref-type="bibr" rid="pntd.0007098.ref067">67</xref>, <xref ref-type="bibr" rid="pntd.0007098.ref068">68</xref>]. However, clinical experience shows that early and small mycetoma lesions are associated with good outcome and prevent severe complications of the disease.</p>
<p>One of the remarkable findings of the current study is the significant increase of IL-37 and IL-35 levels with itraconazole treatment compared to the ketoconazole. A previous study by Friccius and colleagues suggested that the dose of 10 μg/ml itraconazole leads to strong inhibition of the cytokines IL-2, IL-4, IL-9 and IFN-γ and slight inhibition of TNF-α cytokine production in PBMC after 6 and 24 hours of incubation. These results demonstrate that IL-35 and IL-37 can be one of the underline factors associated with inhibition of the cytokines related to Itraconazole [<xref ref-type="bibr" rid="pntd.0007098.ref069">69</xref>].</p>
<p>In conclusion, our study revealed that the levels of IL-37 and IL-35 were consistently positively correlated with different diameters of mycetoma lesions as well as its duration. However, the levels of IL-1β and IL-12 were consistently negatively correlated with different diameters of lesions and the duration of mycetoma infection. The analysis of the risk factors of higher circulatory levels of IL-37 in patients of mycetoma showed a negative significant association with IL-1β cytokine, where a unit increment in IL-1β will decrease the levels of IL-37 by 35.28 pg/ml. Levels of IL-37 among the patients with a mycetoma infection duration ≤ 1 year had significantly decreased on average by 18.45 pg/ml compared to patients with a mycetoma infection duration ≥ 5years (reference group). Furthermore, the risk factors of higher levels of IL-35 in patients of mycetoma revealed a negative significant association with IL-12, as a unit increment in IL-12 decreases the levels of IL-35 decrease by 8.99 pg/ml, <italic>p</italic> &lt; 0.001. Levels of IL-35 among the patients with a mycetoma infection duration ≤ 1 year had significantly decreased (<italic>p</italic> value = 0.002) on average by 41.82 pg/ml compared to patients with a mycetoma infection duration ≥ 5years (reference group). More investigations are needed to explore the mechanism by which IL-35 and IL-37 contribute in the mycetoma infection outcomes. This will help in understanding the role of these cytokines IL-35 and IL-37 in the pathogenesis of mycetoma, and may exploit it as a potential therapeutic target to prevent mycetoma diseases recurrence.</p>
</sec>
<sec id="sec018">
<title>Supporting information</title>
<supplementary-material id="pntd.0007098.s001" mimetype="application/msword" position="float" xlink:href="info:doi/10.1371/journal.pntd.0007098.s001" xlink:type="simple">
<label>S1 Checklist</label>
<caption>
<title>STROBE checklist.</title>
<p>(DOC)</p>
</caption>
</supplementary-material>
</sec>
</body>
<back>
<ack>
<p>The authors are grateful to the patients, controls and their families and the staff at the Mycetoma Research Centre at Soba University Hospital, University of Khartoum-Sudan, for their continued collaboration and generous hospitality during a decade of samples collection. The authors are thankful to Dr. Hamza A., Dundee University, UK for improving the English language and proof reading the Manuscript.</p>
</ack>
<ref-list>
<title>References</title>
<ref id="pntd.0007098.ref001"><label>1</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Fahal</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Mahgoub</surname> <given-names>ES</given-names></name>, <name name-style="western"><surname>Hassan</surname> <given-names>AME</given-names></name>, <name name-style="western"><surname>Abdel-Rahman</surname> <given-names>ME</given-names></name>. (<year>2015</year>) <article-title>Mycetoma in the Sudan: an update from the mycetoma research centre, University of Khartoum, Sudan</article-title>. <source>PLoS Negl Trop Dis</source>.<volume>9</volume>: <fpage>e0003679</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pntd.0003679" xlink:type="simple">10.1371/journal.pntd.0003679</ext-link></comment> <object-id pub-id-type="pmid">25816316</object-id></mixed-citation></ref>
<ref id="pntd.0007098.ref002"><label>2</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Zijlstra</surname> <given-names>EE</given-names></name>, <name name-style="western"><surname>van de Sande</surname> <given-names>WW</given-names></name>, <name name-style="western"><surname>Welsh</surname> <given-names>O</given-names></name>, <name name-style="western"><surname>Goodfellow</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Fahal</surname> <given-names>AH</given-names></name>. (<year>2016</year>) <article-title>Mycetoma: a unique neglected tropical disease</article-title>. <source>The Lancet Infectious Diseases</source>.<volume>16</volume>: <fpage>100</fpage>–<lpage>112</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/S1473-3099(15)00359-X" xlink:type="simple">10.1016/S1473-3099(15)00359-X</ext-link></comment> <object-id pub-id-type="pmid">26738840</object-id></mixed-citation></ref>
<ref id="pntd.0007098.ref003"><label>3</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Fahal</surname> <given-names>AH</given-names></name>, <name name-style="western"><surname>Hassan</surname> <given-names>MA</given-names></name>. (<year>1992</year>) <article-title>Mycetoma</article-title>. <source>Br J Surg</source>.<volume>79</volume>: <fpage>1138</fpage>–<lpage>1141</lpage>. <object-id pub-id-type="pmid">1467883</object-id></mixed-citation></ref>
<ref id="pntd.0007098.ref004"><label>4</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Vera-Cabrera</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Salinas-Carmona</surname> <given-names>MC</given-names></name>, <name name-style="western"><surname>Waksman</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Messeguer-Pérez</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Ocampo-Candiani</surname> <given-names>J</given-names></name>, <etal>et al</etal>. (<year>2012</year>) <article-title>Host defenses in subcutaneous mycoses</article-title>. <source>Clinics in dermatology</source>.<volume>30</volume>: <fpage>382</fpage>–<lpage>388</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.clindermatol.2011.09.008" xlink:type="simple">10.1016/j.clindermatol.2011.09.008</ext-link></comment> <object-id pub-id-type="pmid">22682185</object-id></mixed-citation></ref>
<ref id="pntd.0007098.ref005"><label>5</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>El Hassan</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Fahal</surname> <given-names>AH</given-names></name>, <name name-style="western"><surname>Ahmed</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Ismail</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Veress</surname> <given-names>B</given-names></name>. (<year>2001</year>) <article-title>The immunopathology of actinomycetoma lesions caused by Streptomyces somaliensis</article-title>. <source>Transactions of the Royal Society of Tropical Medicine and Hygiene</source>.<volume>95</volume>: <fpage>89</fpage>–<lpage>92</lpage>. <object-id pub-id-type="pmid">11280076</object-id></mixed-citation></ref>
<ref id="pntd.0007098.ref006"><label>6</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Mahgoub</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Gumaa</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>El Hassan</surname> <given-names>A</given-names></name>. (<year>1976</year>) <article-title>Immunological status of mycetoma patients</article-title>. <source>Bulletin de la Societe de Pathologie Exotique et de ses Filiales</source>.<volume>70</volume>: <fpage>48</fpage>–<lpage>54</lpage>.</mixed-citation></ref>
<ref id="pntd.0007098.ref007"><label>7</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Al Dawi</surname> <given-names>AF</given-names></name>, <name name-style="western"><surname>Mustafa</surname> <given-names>MI</given-names></name>, <name name-style="western"><surname>Fahal</surname> <given-names>AH</given-names></name>, <name name-style="western"><surname>Hassan</surname> <given-names>AME</given-names></name>, <name name-style="western"><surname>Bakhiet</surname> <given-names>SM</given-names></name>, <etal>et al</etal>. (<year>2014</year>) <article-title>The association of HLA-DRB1 and HLA-DQB1 alleles and the occurrence of eumycetoma in Sudanese patients</article-title>. <source>Khartoum Medical Journal.6</source>.</mixed-citation></ref>
<ref id="pntd.0007098.ref008"><label>8</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Meester</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>Rosas-Taraco</surname> <given-names>AG</given-names></name>, <name name-style="western"><surname>Salinas-Carmona</surname> <given-names>MC</given-names></name>. (<year>2013</year>) <article-title>Retnla down-regulation and IL-13-rich environment correlate with inflammation severity in experimental actinomycetoma by Nocardia brasiliensis</article-title>. <source>Pathogens and disease</source>.<volume>67</volume>: <fpage>214</fpage>–<lpage>220</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/2049-632X.12036" xlink:type="simple">10.1111/2049-632X.12036</ext-link></comment> <object-id pub-id-type="pmid">23620185</object-id></mixed-citation></ref>
<ref id="pntd.0007098.ref009"><label>9</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>van Hellemond</surname> <given-names>JJ</given-names></name>, <name name-style="western"><surname>Vonk</surname> <given-names>AG</given-names></name>, <name name-style="western"><surname>de Vogel</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Koelewijn</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Vaessen</surname> <given-names>N</given-names></name>, <etal>et al</etal>. (<year>2013</year>) <article-title>Association of eumycetoma and schistosomiasis</article-title>. <source>PLoS Negl Trop Dis</source>.<volume>7</volume>: <fpage>e2241</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pntd.0002241" xlink:type="simple">10.1371/journal.pntd.0002241</ext-link></comment> <object-id pub-id-type="pmid">23717704</object-id></mixed-citation></ref>
<ref id="pntd.0007098.ref010"><label>10</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Figueiredo</surname> <given-names>RT</given-names></name>, <name name-style="western"><surname>Fernandez</surname> <given-names>PL</given-names></name>, <name name-style="western"><surname>Dutra</surname> <given-names>FF</given-names></name>, <name name-style="western"><surname>González</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Lopes</surname> <given-names>LC</given-names></name>, <etal>et al</etal>. (<year>2010</year>) <article-title>TLR4 recognizes Pseudallescheria boydii conidia and purified rhamnomannans</article-title>. <source>Journal of Biological Chemistry</source>.<volume>285</volume>: <fpage>40714</fpage>–<lpage>40723</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1074/jbc.M110.181255" xlink:type="simple">10.1074/jbc.M110.181255</ext-link></comment> <object-id pub-id-type="pmid">20959459</object-id></mixed-citation></ref>
<ref id="pntd.0007098.ref011"><label>11</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>SALINAS‐CARMONA</surname> <given-names>MC</given-names></name>, <name name-style="western"><surname>TORRES‐LÓPEZ</surname> <given-names>E</given-names></name>. (<year>1996</year>) <article-title>Role of passive humoral immunity in experimental mycetoma by Nocardia brasiliensis</article-title>. <source>Annals of the New York Academy of Sciences</source>.<volume>797</volume>: <fpage>263</fpage>–<lpage>265</lpage>. <object-id pub-id-type="pmid">8993374</object-id></mixed-citation></ref>
<ref id="pntd.0007098.ref012"><label>12</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Welsh</surname> <given-names>O</given-names></name>, <name name-style="western"><surname>Vera-Cabrera</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Welsh</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Salinas</surname> <given-names>MC</given-names></name>. (<year>2012</year>) <article-title>Actinomycetoma and advances in its treatment</article-title>. <source>Clinics in dermatology</source>.<volume>30</volume>: <fpage>372</fpage>–<lpage>381</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.clindermatol.2011.06.027" xlink:type="simple">10.1016/j.clindermatol.2011.06.027</ext-link></comment> <object-id pub-id-type="pmid">22682184</object-id></mixed-citation></ref>
<ref id="pntd.0007098.ref013"><label>13</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Deem</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Doughty</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Beaman</surname> <given-names>B</given-names></name>. (<year>1983</year>) <article-title>Immunologically specific direct T lymphocyte-mediated killing of Nocardia asteroides</article-title>. <source>The Journal of Immunology</source>.<volume>130</volume>: <fpage>2401</fpage>–<lpage>2406</lpage>. <object-id pub-id-type="pmid">6339627</object-id></mixed-citation></ref>
<ref id="pntd.0007098.ref014"><label>14</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Trevino-Villarreal</surname> <given-names>JH</given-names></name>, <name name-style="western"><surname>Vera-Cabrera</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Valero-Guillén</surname> <given-names>PL</given-names></name>, <name name-style="western"><surname>Salinas-Carmona</surname> <given-names>MC</given-names></name>. (<year>2012</year>) <article-title>Nocardia brasiliensis cell wall lipids modulate macrophage and dendritic responses that favor development of experimental actinomycetoma in BALB/c mice</article-title>. <source>Infection and immunity</source>.<volume>80</volume>: <fpage>3587</fpage>–<lpage>3601</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1128/IAI.00446-12" xlink:type="simple">10.1128/IAI.00446-12</ext-link></comment> <object-id pub-id-type="pmid">22851755</object-id></mixed-citation></ref>
<ref id="pntd.0007098.ref015"><label>15</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Di Iorio</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Ferrucci</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Sparvieri</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Cherubini</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Volpato</surname> <given-names>S</given-names></name>, <etal>et al</etal>. (<year>2003</year>) <article-title>Serum IL-1beta levels in health and disease: a population-based study. 'The InCHIANTI study'</article-title>. <source>Cytokine</source>.<volume>22</volume>: <fpage>198</fpage>–<lpage>205</lpage>. <object-id pub-id-type="pmid">12890453</object-id></mixed-citation></ref>
<ref id="pntd.0007098.ref016"><label>16</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Paulus</surname> <given-names>WJ</given-names></name>. (<year>2000</year>) <article-title>Cytokines and heart failure</article-title>. <source>Heart Fail Monit</source>.<volume>1</volume>: <fpage>50</fpage>–<lpage>56</lpage>. <object-id pub-id-type="pmid">12634874</object-id></mixed-citation></ref>
<ref id="pntd.0007098.ref017"><label>17</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Nasr</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Abushouk</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Hamza</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Siddig</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Fahal</surname> <given-names>AH</given-names></name>. (<year>2016</year>) <article-title>Th-1, Th-2 Cytokines Profile among Madurella mycetomatis Eumycetoma Patients</article-title>. <source>PLoS Negl Trop Dis</source>.<volume>10</volume>: <fpage>e0004862</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pntd.0004862" xlink:type="simple">10.1371/journal.pntd.0004862</ext-link></comment> <object-id pub-id-type="pmid">27434108</object-id></mixed-citation></ref>
<ref id="pntd.0007098.ref018"><label>18</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ganesan</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Rathinam</surname> <given-names>VA</given-names></name>, <name name-style="western"><surname>Bossaller</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Army</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Kaiser</surname> <given-names>WJ</given-names></name>, <etal>et al</etal>. (<year>2014</year>) <article-title>Caspase-8 modulates dectin-1 and complement receptor 3-driven IL-1beta production in response to beta-glucans and the fungal pathogen, Candida albicans</article-title>. <source>J Immunol</source>.<volume>193</volume>: <fpage>2519</fpage>–<lpage>2530</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.4049/jimmunol.1400276" xlink:type="simple">10.4049/jimmunol.1400276</ext-link></comment> <object-id pub-id-type="pmid">25063877</object-id></mixed-citation></ref>
<ref id="pntd.0007098.ref019"><label>19</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Nold</surname> <given-names>MF</given-names></name>, <name name-style="western"><surname>Nold-Petry</surname> <given-names>CA</given-names></name>, <name name-style="western"><surname>Zepp</surname> <given-names>JA</given-names></name>, <name name-style="western"><surname>Palmer</surname> <given-names>BE</given-names></name>, <name name-style="western"><surname>Bufler</surname> <given-names>P</given-names></name>, <etal>et al</etal>. (<year>2010</year>) <article-title>IL-37 is a fundamental inhibitor of innate immunity</article-title>. <source>Nat Immunol</source>.<volume>11</volume>: <fpage>1014</fpage>–<lpage>1022</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/ni.1944" xlink:type="simple">10.1038/ni.1944</ext-link></comment> <object-id pub-id-type="pmid">20935647</object-id></mixed-citation></ref>
<ref id="pntd.0007098.ref020"><label>20</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Allam</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Mohamed</surname> <given-names>IA</given-names></name>, <name name-style="western"><surname>Alswat</surname> <given-names>KA</given-names></name>, <name name-style="western"><surname>Abbadi</surname> <given-names>SH</given-names></name>, <name name-style="western"><surname>Nassif</surname> <given-names>R</given-names></name>, <etal>et al</etal>. (<year>2016</year>) <article-title>Association of IL‐37 gene polymorphisms with susceptibility to tuberculosis in Saudi population</article-title>. <source>Microbiology and Immunology</source>.<volume>60</volume>: <fpage>778</fpage>–<lpage>786</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/1348-0421.12444" xlink:type="simple">10.1111/1348-0421.12444</ext-link></comment></mixed-citation></ref>
<ref id="pntd.0007098.ref021"><label>21</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ye</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Ji</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Wen</surname> <given-names>Z</given-names></name>, <name name-style="western"><surname>Zhou</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Hu</surname> <given-names>D</given-names></name>, <etal>et al</etal>. (<year>2014</year>) <article-title>IL-37 inhibits the production of inflammatory cytokines in peripheral blood mononuclear cells of patients with systemic lupus erythematosus: its correlation with disease activity</article-title>. <source>J Transl Med</source>.<volume>12</volume>: <fpage>69</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1186/1479-5876-12-69" xlink:type="simple">10.1186/1479-5876-12-69</ext-link></comment> <object-id pub-id-type="pmid">24629023</object-id></mixed-citation></ref>
<ref id="pntd.0007098.ref022"><label>22</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Li</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Wang</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Liu</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Wang</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Zuo</surname> <given-names>X</given-names></name>, <etal>et al</etal>. (<year>2014</year>) <article-title>The possible role of the novel cytokines il-35 and il-37 in inflammatory bowel disease</article-title>. <source>Mediators Inflamm</source>.<volume>2014</volume>: <fpage>136329</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1155/2014/136329" xlink:type="simple">10.1155/2014/136329</ext-link></comment> <object-id pub-id-type="pmid">25214710</object-id></mixed-citation></ref>
<ref id="pntd.0007098.ref023"><label>23</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Wan</surname> <given-names>ZY</given-names></name>, <name name-style="western"><surname>Sun</surname> <given-names>Z</given-names></name>, <name name-style="western"><surname>Song</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Chen</surname> <given-names>YF</given-names></name>, <name name-style="western"><surname>Zhang</surname> <given-names>WL</given-names></name>, <etal>et al</etal>. (<year>2014</year>) <article-title>Downregulated interleukin 37 expression associated with aggravation of intervertebral disc degeneration</article-title>. <source>Int J Clin Exp Pathol</source>.<volume>7</volume>: <fpage>656</fpage>–<lpage>662</lpage>. <object-id pub-id-type="pmid">24551286</object-id></mixed-citation></ref>
<ref id="pntd.0007098.ref024"><label>24</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Li</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Wang</surname> <given-names>Z</given-names></name>, <name name-style="western"><surname>Yu</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Chen</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Zhang</surname> <given-names>J</given-names></name>, <etal>et al</etal>. (<year>2014</year>) <article-title>Increased expression of IL-37 in patients with Graves’ disease and its contribution to suppression of proinflammatory cytokines production in peripheral blood mononuclear cells</article-title>. <source>PLoS One</source>.<volume>9</volume>: <fpage>e107183</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pone.0107183" xlink:type="simple">10.1371/journal.pone.0107183</ext-link></comment> <object-id pub-id-type="pmid">25226272</object-id></mixed-citation></ref>
<ref id="pntd.0007098.ref025"><label>25</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Boraschi</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Lucchesi</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Hainzl</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Leitner</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Maier</surname> <given-names>E</given-names></name>, <etal>et al</etal>. (<year>2011</year>) <article-title>IL-37: a new anti-inflammatory cytokine of the IL-1 family</article-title>. <source>Eur Cytokine Netw</source>.<volume>22</volume>: <fpage>127</fpage>–<lpage>147</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1684/ecn.2011.0288" xlink:type="simple">10.1684/ecn.2011.0288</ext-link></comment> <object-id pub-id-type="pmid">22047735</object-id></mixed-citation></ref>
<ref id="pntd.0007098.ref026"><label>26</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Banchereau</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Pascual</surname> <given-names>V</given-names></name>, <name name-style="western"><surname>O'Garra</surname> <given-names>A</given-names></name>. (<year>2012</year>) <article-title>From IL-2 to IL-37: the expanding spectrum of anti-inflammatory cytokines</article-title>. <source>Nat Immunol</source>.<volume>13</volume>: <fpage>925</fpage>–<lpage>931</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/ni.2406" xlink:type="simple">10.1038/ni.2406</ext-link></comment> <object-id pub-id-type="pmid">22990890</object-id></mixed-citation></ref>
<ref id="pntd.0007098.ref027"><label>27</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>McNamee</surname> <given-names>EN</given-names></name>, <name name-style="western"><surname>Masterson</surname> <given-names>JC</given-names></name>, <name name-style="western"><surname>Jedlicka</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>McManus</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Grenz</surname> <given-names>A</given-names></name>, <etal>et al</etal>. (<year>2011</year>) <article-title>Interleukin 37 expression protects mice from colitis</article-title>. <source>Proc Natl Acad Sci U S A</source>.<volume>108</volume>: <fpage>16711</fpage>–<lpage>16716</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1073/pnas.1111982108" xlink:type="simple">10.1073/pnas.1111982108</ext-link></comment> <object-id pub-id-type="pmid">21873195</object-id></mixed-citation></ref>
<ref id="pntd.0007098.ref028"><label>28</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>van de Veerdonk</surname> <given-names>FL</given-names></name>, <name name-style="western"><surname>Gresnigt</surname> <given-names>MS</given-names></name>, <name name-style="western"><surname>Oosting</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>van der Meer</surname> <given-names>JW</given-names></name>, <name name-style="western"><surname>Joosten</surname> <given-names>LA</given-names></name>, <etal>et al</etal>. (<year>2015</year>) <article-title>Protective host defense against disseminated candidiasis is impaired in mice expressing human interleukin-37</article-title>. <source>Frontiers in microbiology</source>.<volume>5</volume>: <fpage>762</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fmicb.2014.00762" xlink:type="simple">10.3389/fmicb.2014.00762</ext-link></comment> <object-id pub-id-type="pmid">25620965</object-id></mixed-citation></ref>
<ref id="pntd.0007098.ref029"><label>29</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Moretti</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Bozza</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Oikonomou</surname> <given-names>V</given-names></name>, <name name-style="western"><surname>Renga</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Casagrande</surname> <given-names>A</given-names></name>, <etal>et al</etal>. (<year>2014</year>) <article-title>IL-37 inhibits inflammasome activation and disease severity in murine aspergillosis</article-title>. <source>PLoS Pathog</source>.<volume>10</volume>: <fpage>e1004462</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.ppat.1004462" xlink:type="simple">10.1371/journal.ppat.1004462</ext-link></comment> <object-id pub-id-type="pmid">25375146</object-id></mixed-citation></ref>
<ref id="pntd.0007098.ref030"><label>30</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Luo</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Cai</surname> <given-names>X</given-names></name>, <name name-style="western"><surname>Liu</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Wang</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Nold-Petry</surname> <given-names>CA</given-names></name>, <etal>et al</etal>. (<year>2014</year>) <article-title>Suppression of antigen-specific adaptive immunity by IL-37 via induction of tolerogenic dendritic cells</article-title>. <source>Proc Natl Acad Sci U S A</source>.<volume>111</volume>: <fpage>15178</fpage>–<lpage>15183</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1073/pnas.1416714111" xlink:type="simple">10.1073/pnas.1416714111</ext-link></comment> <object-id pub-id-type="pmid">25294929</object-id></mixed-citation></ref>
<ref id="pntd.0007098.ref031"><label>31</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ashman</surname> <given-names>RB</given-names></name>, <name name-style="western"><surname>Vijayan</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Wells</surname> <given-names>CA</given-names></name>. (<year>2011</year>) <article-title>IL-12 and related cytokines: function and regulatory implications in Candida albicans infection</article-title>. <source>Clin Dev Immunol</source>.<volume>2011</volume>: <fpage>686597</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1155/2011/686597" xlink:type="simple">10.1155/2011/686597</ext-link></comment> <object-id pub-id-type="pmid">21052539</object-id></mixed-citation></ref>
<ref id="pntd.0007098.ref032"><label>32</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>O'Garra</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Murphy</surname> <given-names>KM</given-names></name>. (<year>2009</year>) <article-title>From IL-10 to IL-12: how pathogens and their products stimulate APCs to induce T(H)1 development</article-title>. <source>Nat Immunol</source>.<volume>10</volume>: <fpage>929</fpage>–<lpage>932</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/ni0909-929" xlink:type="simple">10.1038/ni0909-929</ext-link></comment> <object-id pub-id-type="pmid">19692989</object-id></mixed-citation></ref>
<ref id="pntd.0007098.ref033"><label>33</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Collison</surname> <given-names>LW</given-names></name>, <name name-style="western"><surname>Workman</surname> <given-names>CJ</given-names></name>, <name name-style="western"><surname>Kuo</surname> <given-names>TT</given-names></name>, <name name-style="western"><surname>Boyd</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Wang</surname> <given-names>Y</given-names></name>, <etal>et al</etal>. (<year>2007</year>) <article-title>The inhibitory cytokine IL-35 contributes to regulatory T-cell function</article-title>. <source>Nature</source>.<volume>450</volume>: <fpage>566</fpage>–<lpage>569</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/nature06306" xlink:type="simple">10.1038/nature06306</ext-link></comment> <object-id pub-id-type="pmid">18033300</object-id></mixed-citation></ref>
<ref id="pntd.0007098.ref034"><label>34</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Vignali</surname> <given-names>DA</given-names></name>, <name name-style="western"><surname>Kuchroo</surname> <given-names>VK</given-names></name>. (<year>2012</year>) <article-title>IL-12 family cytokines: immunological playmakers</article-title>. <source>Nature immunology</source>.<volume>13</volume>: <fpage>722</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/ni.2366" xlink:type="simple">10.1038/ni.2366</ext-link></comment> <object-id pub-id-type="pmid">22814351</object-id></mixed-citation></ref>
<ref id="pntd.0007098.ref035"><label>35</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Shen</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Roch</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Lampropoulou</surname> <given-names>V</given-names></name>, <name name-style="western"><surname>O’Connor</surname> <given-names>RA</given-names></name>, <name name-style="western"><surname>Stervbo</surname> <given-names>U</given-names></name>, <etal>et al</etal>. (<year>2014</year>) <article-title>IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases</article-title>. <source>Nature</source>.<volume>507</volume>: <fpage>366</fpage>–<lpage>370</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/nature12979" xlink:type="simple">10.1038/nature12979</ext-link></comment> <object-id pub-id-type="pmid">24572363</object-id></mixed-citation></ref>
<ref id="pntd.0007098.ref036"><label>36</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Dixon</surname> <given-names>KO</given-names></name>, <name name-style="western"><surname>der Kooij</surname> <given-names>SW</given-names></name>, <name name-style="western"><surname>Vignali</surname> <given-names>DA</given-names></name>, <name name-style="western"><surname>Kooten</surname> <given-names>C</given-names></name>. (<year>2015</year>) <article-title>Human tolerogenic dendritic cells produce IL‐35 in the absence of other IL‐12 family members</article-title>. <source>European journal of immunology</source>.<volume>45</volume>: <fpage>1736</fpage>–<lpage>1747</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1002/eji.201445217" xlink:type="simple">10.1002/eji.201445217</ext-link></comment></mixed-citation></ref>
<ref id="pntd.0007098.ref037"><label>37</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Choi</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Leung</surname> <given-names>PS</given-names></name>, <name name-style="western"><surname>Bowlus</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Gershwin</surname> <given-names>ME</given-names></name>. (<year>2015</year>) <article-title>IL-35 and autoimmunity: a comprehensive perspective</article-title>. <source>Clinical reviews in allergy &amp; immunology</source>.<volume>49</volume>: <fpage>327</fpage>–<lpage>332</lpage>.</mixed-citation></ref>
<ref id="pntd.0007098.ref038"><label>38</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Tirotta</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Duncker</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Oak</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Klaus</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Tsukamoto</surname> <given-names>MR</given-names></name>, <etal>et al</etal>. (<year>2013</year>) <article-title>Epstein–Barr virus-induced gene 3 negatively regulates neuroinflammation and T cell activation following coronavirus-induced encephalomyelitis</article-title>. <source>Journal of neuroimmunology</source>.<volume>254</volume>: <fpage>110</fpage>–<lpage>116</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.jneuroim.2012.10.005" xlink:type="simple">10.1016/j.jneuroim.2012.10.005</ext-link></comment> <object-id pub-id-type="pmid">23102608</object-id></mixed-citation></ref>
<ref id="pntd.0007098.ref039"><label>39</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kochetkova</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>Golden</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Holderness</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Callis</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Pascual</surname> <given-names>DW</given-names></name>. (<year>2010</year>) <article-title>IL-35 stimulation of CD39+ regulatory T cells confers protection against collagen II-induced arthritis via the production of IL-10</article-title>. <source>The Journal of Immunology</source>.<volume>184</volume>: <fpage>7144</fpage>–<lpage>7153</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.4049/jimmunol.0902739" xlink:type="simple">10.4049/jimmunol.0902739</ext-link></comment> <object-id pub-id-type="pmid">20483737</object-id></mixed-citation></ref>
<ref id="pntd.0007098.ref040"><label>40</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Niedbala</surname> <given-names>W</given-names></name>, <name name-style="western"><surname>Wei</surname> <given-names>Xq</given-names></name>, <name name-style="western"><surname>Cai</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Hueber</surname> <given-names>AJ</given-names></name>, <name name-style="western"><surname>Leung</surname> <given-names>BP</given-names></name>, <etal>et al</etal>. (<year>2007</year>) <article-title>IL‐35 is a novel cytokine with therapeutic effects against collagen‐induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells</article-title>. <source>European journal of immunology</source>.<volume>37</volume>: <fpage>3021</fpage>–<lpage>3029</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1002/eji.200737810" xlink:type="simple">10.1002/eji.200737810</ext-link></comment> <object-id pub-id-type="pmid">17874423</object-id></mixed-citation></ref>
<ref id="pntd.0007098.ref041"><label>41</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Huang</surname> <given-names>C-H</given-names></name>, <name name-style="western"><surname>Loo</surname> <given-names>EX-L</given-names></name>, <name name-style="western"><surname>Kuo</surname> <given-names>I-C</given-names></name>, <name name-style="western"><surname>Soh</surname> <given-names>GH</given-names></name>, <name name-style="western"><surname>Goh</surname> <given-names>DL-M</given-names></name>, <etal>et al</etal>. (<year>2011</year>) <article-title>Airway inflammation and IgE production induced by dust mite allergen-specific memory/effector Th2 cell line can be effectively attenuated by IL-35</article-title>. <source>The Journal of Immunology</source>.<volume>187</volume>: <fpage>462</fpage>–<lpage>471</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.4049/jimmunol.1100259" xlink:type="simple">10.4049/jimmunol.1100259</ext-link></comment> <object-id pub-id-type="pmid">21613618</object-id></mixed-citation></ref>
<ref id="pntd.0007098.ref042"><label>42</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Whitehead</surname> <given-names>GS</given-names></name>, <name name-style="western"><surname>Wilson</surname> <given-names>RH</given-names></name>, <name name-style="western"><surname>Nakano</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Burch</surname> <given-names>LH</given-names></name>, <name name-style="western"><surname>Nakano</surname> <given-names>H</given-names></name>, <etal>et al</etal>. (<year>2012</year>) <article-title>IL-35 production by inducible costimulator (ICOS)–positive regulatory T cells reverses established IL-17–dependent allergic airways disease</article-title>. <source>Journal of Allergy and Clinical Immunology</source>.<volume>129</volume>: <fpage>207</fpage>–<lpage>215. e205</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.jaci.2011.08.009" xlink:type="simple">10.1016/j.jaci.2011.08.009</ext-link></comment> <object-id pub-id-type="pmid">21906794</object-id></mixed-citation></ref>
<ref id="pntd.0007098.ref043"><label>43</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Cao</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Xu</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Lin</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Tao</surname> <given-names>X</given-names></name>, <name name-style="western"><surname>Xiang</surname> <given-names>Y</given-names></name>, <etal>et al</etal>. (<year>2015</year>) <article-title>IL-35 is elevated in clinical and experimental sepsis and mediates inflammation</article-title>. <source>Clinical Immunology</source>.<volume>161</volume>: <fpage>89</fpage>–<lpage>95</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.clim.2015.08.016" xlink:type="simple">10.1016/j.clim.2015.08.016</ext-link></comment> <object-id pub-id-type="pmid">26342538</object-id></mixed-citation></ref>
<ref id="pntd.0007098.ref044"><label>44</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kong</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Liu</surname> <given-names>G-B</given-names></name>, <name name-style="western"><surname>Zhang</surname> <given-names>J-A</given-names></name>, <name name-style="western"><surname>Fu</surname> <given-names>X-X</given-names></name>, <name name-style="western"><surname>Xiang</surname> <given-names>W-Y</given-names></name>, <etal>et al</etal>. (<year>2016</year>) <article-title>Elevated serum IL-35 and increased expression of IL-35-p35 or-EBI3 in CD4+ CD25+ T cells in patients with active tuberculosis</article-title>. <source>American journal of translational research</source>.<volume>8</volume>: <fpage>623</fpage>. <object-id pub-id-type="pmid">27158354</object-id></mixed-citation></ref>
<ref id="pntd.0007098.ref045"><label>45</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ahmed</surname> <given-names>AA</given-names></name>, <name name-style="western"><surname>van de Sande</surname> <given-names>W</given-names></name>, <name name-style="western"><surname>Fahal</surname> <given-names>AH</given-names></name>. (<year>2017</year>) <article-title>Mycetoma laboratory diagnosis: Review article</article-title>. <source>PLoS Negl Trop Dis</source>.<volume>11</volume>: <fpage>e0005638</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pntd.0005638" xlink:type="simple">10.1371/journal.pntd.0005638</ext-link></comment> <object-id pub-id-type="pmid">28837657</object-id></mixed-citation></ref>
<ref id="pntd.0007098.ref046"><label>46</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Mei</surname> <given-names>JV</given-names></name>, <name name-style="western"><surname>Alexander</surname> <given-names>JR</given-names></name>, <name name-style="western"><surname>Adam</surname> <given-names>BW</given-names></name>, <name name-style="western"><surname>Hannon</surname> <given-names>WH</given-names></name>. (<year>2001</year>) <article-title>Use of filter paper for the collection and analysis of human whole blood specimens</article-title>. <source>J Nutr</source>.<volume>131</volume>: <fpage>1631S</fpage>–<lpage>1636S</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/jn/131.5.1631S" xlink:type="simple">10.1093/jn/131.5.1631S</ext-link></comment> <object-id pub-id-type="pmid">11340130</object-id></mixed-citation></ref>
<ref id="pntd.0007098.ref047"><label>47</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Mercader</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Featherstone</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Bellini</surname> <given-names>WJ</given-names></name>. (<year>2006</year>) <article-title>Comparison of available methods to elute serum from dried blood spot samples for measles serology</article-title>. <source>J Virol Methods</source>.<volume>137</volume>: <fpage>140</fpage>–<lpage>149</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.jviromet.2006.06.018" xlink:type="simple">10.1016/j.jviromet.2006.06.018</ext-link></comment> <object-id pub-id-type="pmid">16860401</object-id></mixed-citation></ref>
<ref id="pntd.0007098.ref048"><label>48</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Parker</surname> <given-names>SP</given-names></name>, <name name-style="western"><surname>Cubitt</surname> <given-names>WD</given-names></name>. (<year>1999</year>) <article-title>The use of the dried blood spot sample in epidemiological studies</article-title>. <source>J Clin Pathol</source>.<volume>52</volume>: <fpage>633</fpage>–<lpage>639</lpage>. <object-id pub-id-type="pmid">10655983</object-id></mixed-citation></ref>
<ref id="pntd.0007098.ref049"><label>49</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sibbald</surname> <given-names>B</given-names></name>. (<year>2003</year>) <article-title>Helsinki Declaration revisited over concerns about human subjects</article-title>. <source>Cmaj</source>.<volume>169</volume>: <fpage>1066</fpage>. <object-id pub-id-type="pmid">14609989</object-id></mixed-citation></ref>
<ref id="pntd.0007098.ref050"><label>50</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Rieg</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Meier</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Fähnrich</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Huth</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Wagner</surname> <given-names>D</given-names></name>, <etal>et al</etal>. (<year>2010</year>) <article-title>Differential activity of innate defense antimicrobial peptides against Nocardia species</article-title>. <source>BMC Microbiology</source>.<volume>10</volume>: <fpage>61</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1186/1471-2180-10-61" xlink:type="simple">10.1186/1471-2180-10-61</ext-link></comment> <object-id pub-id-type="pmid">20178618</object-id></mixed-citation></ref>
<ref id="pntd.0007098.ref051"><label>51</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>LeibundGut-Landmann</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Wüthrich</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Hohl</surname> <given-names>TM</given-names></name>. (<year>2012</year>) <article-title>Immunity to fungi</article-title>. <source>Current opinion in immunology</source>.<volume>24</volume>: <fpage>449</fpage>–<lpage>458</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.coi.2012.04.007" xlink:type="simple">10.1016/j.coi.2012.04.007</ext-link></comment> <object-id pub-id-type="pmid">22613091</object-id></mixed-citation></ref>
<ref id="pntd.0007098.ref052"><label>52</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Franzenburg</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Fraune</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Künzel</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Baines</surname> <given-names>JF</given-names></name>, <name name-style="western"><surname>Domazet-Lošo</surname> <given-names>T</given-names></name>, <etal>et al</etal>. (<year>2012</year>) <article-title>MyD88-deficient Hydra reveal an ancient function of TLR signaling in sensing bacterial colonizers</article-title>. <source>Proceedings of the National Academy of Sciences</source>.<volume>109</volume>: <fpage>19374</fpage>–<lpage>19379</lpage>.</mixed-citation></ref>
<ref id="pntd.0007098.ref053"><label>53</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Taghavi</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Khosravi</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Mortaz</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Nikaein</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Athari</surname> <given-names>SS</given-names></name>. (<year>2017</year>) <article-title>Role of pathogen-associated molecular patterns (PAMPS) in immune responses to fungal infections</article-title>. <source>European journal of pharmacology</source>.<volume>808</volume>: <fpage>8</fpage>–<lpage>13</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.ejphar.2016.11.013" xlink:type="simple">10.1016/j.ejphar.2016.11.013</ext-link></comment> <object-id pub-id-type="pmid">27851904</object-id></mixed-citation></ref>
<ref id="pntd.0007098.ref054"><label>54</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Conti</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Caraffa</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Kritas</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Ronconi</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Fulcheri</surname> <given-names>M</given-names></name>. (<year>2017</year>) <article-title>Alexithymia and its relationships with inflammatory response mediated by IL-1 family members</article-title>. <source>Journal of biological regulators and homeostatic agents</source>.<volume>31</volume>: <fpage>21</fpage>–<lpage>28</lpage>.</mixed-citation></ref>
<ref id="pntd.0007098.ref055"><label>55</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Rivera-Mariani</surname> <given-names>FE</given-names></name>, <name name-style="western"><surname>Vysyaraju</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Negherbon</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Levetin</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Horner</surname> <given-names>WE</given-names></name>, <etal>et al</etal>. (<year>2014</year>) <article-title>Comparison of the interleukin-1β-inducing potency of allergenic spores from higher fungi (basidiomycetes) in a cryopreserved human whole blood system</article-title>. <source>International archives of allergy and immunology</source>.<volume>163</volume>: <fpage>154</fpage>–<lpage>162</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1159/000357036" xlink:type="simple">10.1159/000357036</ext-link></comment> <object-id pub-id-type="pmid">24356469</object-id></mixed-citation></ref>
<ref id="pntd.0007098.ref056"><label>56</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Cavalli</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Dinarello</surname> <given-names>CA</given-names></name>. (<year>2018</year>) <article-title>Suppression of inflammation and acquired immunity by IL‐37</article-title>. <source>Immunological reviews</source>.<volume>281</volume>: <fpage>179</fpage>–<lpage>190</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/imr.12605" xlink:type="simple">10.1111/imr.12605</ext-link></comment> <object-id pub-id-type="pmid">29247987</object-id></mixed-citation></ref>
<ref id="pntd.0007098.ref057"><label>57</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Conti</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Tettamanti</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Mastrangelo</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Ronconi</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Frydas</surname> <given-names>I</given-names></name>, <etal>et al</etal>. (<year>2018</year>) <article-title>Impact of Fungi on Immune Responses</article-title>. <source>Clinical therapeutics</source>.</mixed-citation></ref>
<ref id="pntd.0007098.ref058"><label>58</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Zhan</surname> <given-names>Q</given-names></name>, <name name-style="western"><surname>Zeng</surname> <given-names>Q</given-names></name>, <name name-style="western"><surname>Song</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Zhai</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Xu</surname> <given-names>D</given-names></name>, <etal>et al</etal>. (<year>2017</year>) <article-title>IL-37 suppresses MyD88-mediated inflammatory responses in human aortic valve interstitial cells</article-title>. <source>Molecular Medicine</source>.<volume>23</volume>: <fpage>83</fpage>. <object-id pub-id-type="pmid">28362018</object-id></mixed-citation></ref>
<ref id="pntd.0007098.ref059"><label>59</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Huang</surname> <given-names>Z</given-names></name>, <name name-style="western"><surname>Gao</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Chi</surname> <given-names>X</given-names></name>, <name name-style="western"><surname>Hu</surname> <given-names>YW</given-names></name>, <name name-style="western"><surname>Zheng</surname> <given-names>L</given-names></name>, <etal>et al</etal>. (<year>2015</year>) <article-title>IL-37 Expression is Upregulated in Patients with Tuberculosis and Induces Macrophages Towards an M2-like Phenotype</article-title>. <source>Scand J Immunol</source>.<volume>82</volume>: <fpage>370</fpage>–<lpage>379</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/sji.12326" xlink:type="simple">10.1111/sji.12326</ext-link></comment> <object-id pub-id-type="pmid">26073153</object-id></mixed-citation></ref>
<ref id="pntd.0007098.ref060"><label>60</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Murray</surname> <given-names>PJ</given-names></name>, <name name-style="western"><surname>Wynn</surname> <given-names>TA</given-names></name>. (<year>2011</year>) <article-title>Obstacles and opportunities for understanding macrophage polarization</article-title>. <source>Journal of leukocyte biology</source>.<volume>89</volume>: <fpage>557</fpage>–<lpage>563</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1189/jlb.0710409" xlink:type="simple">10.1189/jlb.0710409</ext-link></comment> <object-id pub-id-type="pmid">21248152</object-id></mixed-citation></ref>
<ref id="pntd.0007098.ref061"><label>61</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Schreiber</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Ehlers</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Heitmann</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Rausch</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Mages</surname> <given-names>J</given-names></name>, <etal>et al</etal>. (<year>2009</year>) <article-title>Autocrine IL-10 induces hallmarks of alternative activation in macrophages and suppresses antituberculosis effector mechanisms without compromising T cell immunity</article-title>. <source>The Journal of Immunology</source>.<volume>183</volume>: <fpage>1301</fpage>–<lpage>1312</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.4049/jimmunol.0803567" xlink:type="simple">10.4049/jimmunol.0803567</ext-link></comment> <object-id pub-id-type="pmid">19561100</object-id></mixed-citation></ref>
<ref id="pntd.0007098.ref062"><label>62</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>El Kasmi</surname> <given-names>KC</given-names></name>, <name name-style="western"><surname>Qualls</surname> <given-names>JE</given-names></name>, <name name-style="western"><surname>Pesce</surname> <given-names>JT</given-names></name>, <name name-style="western"><surname>Smith</surname> <given-names>AM</given-names></name>, <name name-style="western"><surname>Thompson</surname> <given-names>RW</given-names></name>, <etal>et al</etal>. (<year>2008</year>) <article-title>Toll-like receptor–induced arginase 1 in macrophages thwarts effective immunity against intracellular pathogens</article-title>. <source>Nature immunology</source>.<volume>9</volume>: <fpage>1399</fpage>–<lpage>1406</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/ni.1671" xlink:type="simple">10.1038/ni.1671</ext-link></comment> <object-id pub-id-type="pmid">18978793</object-id></mixed-citation></ref>
<ref id="pntd.0007098.ref063"><label>63</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Du</surname> <given-names>W-X</given-names></name>, <name name-style="western"><surname>He</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Jiang</surname> <given-names>H-Y</given-names></name>, <name name-style="western"><surname>Ai</surname> <given-names>Q</given-names></name>, <name name-style="western"><surname>Yu</surname> <given-names>J-L</given-names></name>. (<year>2016</year>) <article-title>Interleukin 35: A novel candidate biomarker to diagnose early onset sepsis in neonates</article-title>. <source>Clinica Chimica Acta</source>.<volume>462</volume>: <fpage>90</fpage>–<lpage>95</lpage>.</mixed-citation></ref>
<ref id="pntd.0007098.ref064"><label>64</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Li</surname> <given-names>X</given-names></name>, <name name-style="western"><surname>Tian</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Dong</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Zhu</surname> <given-names>Q</given-names></name>, <name name-style="western"><surname>Wang</surname> <given-names>Y</given-names></name>, <etal>et al</etal>. (<year>2015</year>) <article-title>IL-35 inhibits HBV antigen-specific IFN-γ-producing CTLs in vitro</article-title>. <source>Clinical Science</source>.<volume>129</volume>: <fpage>395</fpage>–<lpage>404</lpage>. <object-id pub-id-type="pmid">25869609</object-id></mixed-citation></ref>
<ref id="pntd.0007098.ref065"><label>65</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hernández-Hernández</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>López-Martínez</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Méndez-Tovar</surname> <given-names>LJ</given-names></name>, <name name-style="western"><surname>Manzano-Gayosso</surname> <given-names>P</given-names></name>. (<year>1995</year>) <article-title>Nocardia brasiliensis: in vitro and in vivo growth response to steroid sex hormones</article-title>. <source>Mycopathologia</source>.<volume>132</volume>: <fpage>79</fpage>–<lpage>85</lpage>. <object-id pub-id-type="pmid">8819830</object-id></mixed-citation></ref>
<ref id="pntd.0007098.ref066"><label>66</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Fahal</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Hassan</surname> <given-names>AME</given-names></name>, <name name-style="western"><surname>Abdel-Rahman</surname> <given-names>ME</given-names></name>, <name name-style="western"><surname>Alshambaty</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Hashim</surname> <given-names>A</given-names></name>, <etal>et al</etal>. (<year>2014</year>) <article-title>A new model for management of mycetoma in the Sudan</article-title>. <source>PLoS neglected tropical diseases</source>.<volume>8</volume>: <fpage>e3271</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pntd.0003271" xlink:type="simple">10.1371/journal.pntd.0003271</ext-link></comment> <object-id pub-id-type="pmid">25356640</object-id></mixed-citation></ref>
<ref id="pntd.0007098.ref067"><label>67</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Suleiman</surname> <given-names>SH</given-names></name>, <name name-style="western"><surname>Wadaella el</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Fahal</surname> <given-names>AH</given-names></name>. (<year>2016</year>) <article-title>The Surgical Treatment of Mycetoma</article-title>. <source>PLoS Negl Trop Dis</source>.<volume>10</volume>: <fpage>e0004690</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pntd.0004690" xlink:type="simple">10.1371/journal.pntd.0004690</ext-link></comment> <object-id pub-id-type="pmid">27336736</object-id></mixed-citation></ref>
<ref id="pntd.0007098.ref068"><label>68</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Wadal</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Elhassan</surname> <given-names>TA</given-names></name>, <name name-style="western"><surname>Zein</surname> <given-names>HA</given-names></name>, <name name-style="western"><surname>Abdel-Rahman</surname> <given-names>ME</given-names></name>, <name name-style="western"><surname>Fahal</surname> <given-names>AH</given-names></name>. (<year>2016</year>) <article-title>Predictors of Post-operative Mycetoma Recurrence Using Machine-Learning Algorithms: The Mycetoma Research Center Experience</article-title>. <source>PLoS Negl Trop Dis</source>.<volume>10</volume>: <fpage>e0005007</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pntd.0005007" xlink:type="simple">10.1371/journal.pntd.0005007</ext-link></comment> <object-id pub-id-type="pmid">27798643</object-id></mixed-citation></ref>
<ref id="pntd.0007098.ref069"><label>69</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Friccius</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Pohla</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Adibzadeh</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Siegels-Hubenthal</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Schenk</surname> <given-names>A</given-names></name>, <etal>et al</etal>. (<year>1992</year>) <article-title>The effects of the antifungal azoles itraconazole, fluconazole, ketoconazole and miconazole on cytokine gene expression in human lymphoid cells</article-title>. <source>Int J Immunopharmacol</source>.<volume>14</volume>: <fpage>791</fpage>–<lpage>799</lpage>. <object-id pub-id-type="pmid">1380951</object-id></mixed-citation></ref>
</ref-list>
</back>
</article>